[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 512
1. Vauhkonen H, Böhling T, Eissa S, Shoman S, Knuutila S: Can bladder adenocarcinomas be distinguished from schistosomiasis-associated bladder cancers by using array comparative genomic hybridization analysis? Cancer Genet Cytogenet; 2007 Sep;177(2):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can bladder adenocarcinomas be distinguished from schistosomiasis-associated bladder cancers by using array comparative genomic hybridization analysis?
  • Bladder cancer is the most common malignancy in many tropical and subtropical areas, correlating well with the endemicity of schistostomiasis.
  • The majority of schistostomiasis-associated (SA) bladder cancers are squamous cell cancers, whereas the majority of non-SA cases in the Western world are transitional cell cancers, suggesting different carcinogenetic mechanisms.
  • Comparison of the DNA copy number profiles to previously reported profiles of SA transitional cell carcinoma and squamous cell carcinoma revealed similarities (e.g., gains at 5p and 8q), as well as differences (e.g., TCC- and SCC-associated losses at 18p and 20p, and adenocarcinoma-associated gains at 20q).
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Carcinoma, Transitional Cell / genetics. Gene Expression Profiling. Nucleic Acid Hybridization. Schistosomiasis / complications. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Schistosomiasis.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Genet Cytogenet. 2008 Jan 15;180(2):160-2 [18206545.001]
  • (PMID = 17854674.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


2. Autorino R, Di Lorenzo G, Damiano R, Giannarini G, De Sio M, Cheng L, Montironi R: Pathology of the prostate in radical cystectomy specimens: a critical review. Surg Oncol; 2009 Mar;18(1):73-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The reported incidence of prostate adenocarcinoma in cystectomy specimens is highly variable and mostly depending on the histopathology technique of sampling.
  • The clinical significance of these incidentally discovered cancers remains questionable, as the outcome of patients depends on the prognosis of the bladder tumor.
  • For those candidates for prostate sparing surgery, it seems reasonable to include a routine prostate biopsy in the standard preoperative work-up as relevant PSA values to exclude cancer are lacking.
  • It has been suggested that multifocal bladder tumors, CIS in the bladder and bladder tumor location in the bladder neck are independent risk factors for prostatic urothelial carcinoma.
  • Poorly differentiated prostate adenocarcinoma and urothelial carcinoma often share overlapping morphologic features and it can be sometimes difficult to differentiate between these two entities.
  • [MeSH-major] Cystectomy. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / surgery


3. Sternberg CN: Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol; 2006 Aug 20;24(24):3819-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are nomograms better than currently available stage groupings for bladder cancer?
  • [MeSH-major] Cystectomy. Lymph Nodes / pathology. Nomograms. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Predictive Value of Tests. Prognosis. Research Design. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2004 Jul 15;22(14):2781-9 [15199091.001]
  • [CommentOn] J Clin Oncol. 2006 Aug 20;24(24):3967-72 [16864855.001]
  • (PMID = 16864852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Soares MJ, Neves T, Covita A, Monteiro P, Canhoto A, Nogueira R, Barreto JL, Mendonça JC, Maya M, Monteiro H: [Bladder adenocarcinoma. Case report]. Arch Esp Urol; 2008 Sep;61(7):828-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder adenocarcinoma. Case report].
  • [Transliterated title] Adenocarcinoma vesical. Aportación de un caso clínico.
  • OBJECTIVE: Primary bladder adenocarcinoma is a rare entity.
  • METHOD/RESULTS: A 74 year old female patient presents to the emergency department with complaints of gross hematúria not accompanied by lower urinary tract symptoms.
  • Diagnostic work-up included renal and bladder ultrasound, cistoscopy and abdomino-pelvic C. T. scan.
  • Trans-urethral resection revealed an invasive adenocarcinoma.
  • The bladder specimen showed primary bladder adenocarcinoma, pT3aNO.
  • At 6 months of follow-up, the patient does not present disease progression or surgical complications.
  • CONCLUSION: Primary bladder adenocarcinoma is rare.
  • [MeSH-major] Adenocarcinoma. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972921.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 17
  •  go-up   go-down


5. Ide H, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M: The predictors of local recurrence after radical cystectomy in patients with invasive bladder cancer. Jpn J Clin Oncol; 2008 May;38(5):360-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The predictors of local recurrence after radical cystectomy in patients with invasive bladder cancer.
  • METHODS: We identified a study population of 146 consecutive patients treated surgically for invasive bladder cancer at our institution between 1987 and 2003.
  • The presence of concomitant adenocarcinoma component, pathological nodal involvement and the number of retrieved lymph nodes were independent predictors of local recurrence.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Cystectomy. Lymph Nodes / pathology. Neoplasm Recurrence, Local / prevention & control. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Vascular Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490370.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Ashman JB, Zelefsky MJ, Hunt MS, Leibel SA, Fuks Z: Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):765-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.
  • PURPOSE: To investigate the correlations between observed clinical morbidity and dosimetric parameters for whole pelvic radiotherapy (WPRT) for prostate cancer using either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT).
  • METHODS AND MATERIALS: Between December 1996 and January 2002, 27 patients with prostate adenocarcinoma were treated with conformal WPRT as part of their definitive treatment.
  • Dose-volume histograms for the bowel, bladder, and rectum were compared for the three techniques.
  • Acute and late genitourinary toxicity did not appear significantly increased by the addition of conformal WPRT.
  • CONCLUSIONS: Compared to conventional 2D planning, conformal planning for WPRT resulted in significant reductions in the doses delivered to the bowel, rectum, and bladder.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon / radiation effects. Diarrhea / etiology. Humans. Intestine, Small / radiation effects. Male. Middle Aged. Pelvis. Radiation Dosage. Radiotherapy, Intensity-Modulated / adverse effects. Radiotherapy, Intensity-Modulated / methods. Rectum / radiation effects. Urinary Bladder / radiation effects. Urination Disorders / etiology


7. Zhang X, Gupta R, Nicastri AD: Bladder adenocarcinoma following gastrocystoplasty. J Pediatr Urol; 2010 Oct;6(5):525-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder adenocarcinoma following gastrocystoplasty.
  • Bladder augmentation with segments of small bowel (ileocystoplasty), large intestine (colocystoplasty) or stomach (gastrocystoplasty) has been used to treat patients with small or noncompliant bladders by increasing the capacity or compliance.
  • Carcinomas following gastrocystoplasty have been observed in the segments of stomach; however, to our knowledge, carcinoma arising in the residual native bladder has not been reported.
  • We report the first case of adenocarcinoma arising in the residual native bladder in association with intestinal metaplasia and dysplasia of bladder mucosa 17 years following gastrocystoplasty.
  • Intestinal metaplasia secondary to recurrent urinary infection, chronic inflammation, and some form of irritation may potentiate the development of native bladder adenocarcinoma.
  • Patients with gastrocystoplasty are at an increased risk for carcinoma in stomach segments and require close long-term follow up; however, the risk of carcinoma in native bladder is still unclear.
  • [MeSH-major] Adenocarcinoma / etiology. Urinary Bladder / surgery. Urinary Bladder Neoplasms / etiology. Urologic Surgical Procedures / adverse effects

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20392671.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Di Carlo A, Terracciano D, Mariano A, Macchia V: Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol Rep; 2006 May;15(5):1321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
  • By gelatin zymography, we verified MMP activity in the urine of patients with bladder cancer.
  • Of these patients, 10 had well-, 8 had moderately and 7 had poorly differentiated bladder cancer.
  • Moreover, MMP-9 content is enhanced in the urine from patients with high-grade and advanced-stage bladder tumors.
  • Finally, we determined the urinary levels of urinary bladder cancer (UBC), tissue polypeptide-specific antigen (TPS) and protein 22 of nuclear matrix (NMP22).
  • The levels of TPS and NMP-22 were higher in G3 bladder cancer than in G1 and G2 neoplasias.
  • The urinary values of these two biomarkers correlated with the increase in MMP-9 lytic activity in high-grade and advanced-stage bladder cancer.
  • [MeSH-major] Adenocarcinoma / urine. Matrix Metalloproteinase 2 / urine. Matrix Metalloproteinase 9 / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / urine. Case-Control Studies. Cathepsin B / urine. Female. Humans. Male. Middle Aged. Neoplasm Staging. Nuclear Proteins / urine. Peptides / urine. Urinary Bladder / metabolism. Urokinase-Type Plasminogen Activator / urine

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596205.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Peptides; 0 / nuclear matrix protein 22; 0 / tissue polypeptide specific antigen; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.22.1 / Cathepsin B; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


9. Sakuragi N, Todo Y, Kudo M, Yamamoto R, Sato T: A systematic nerve-sparing radical hysterectomy technique in invasive cervical cancer for preserving postsurgical bladder function. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):389-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic nerve-sparing radical hysterectomy technique in invasive cervical cancer for preserving postsurgical bladder function.
  • The objective of this study is to describe a technique for preserving the autonomic nerve systematically, including the hypogastric nerves, pelvic splanchnic nerves, and pelvic plexus and its vesical branches, based on anatomic considerations for the autonomic nerves innervating the urinary bladder, in radical hysterectomies and to assess postsurgical bladder function.
  • A nerve-sparing radical hysterectomy was carried out on 27 consecutive patients with uterine cervical cancer treated between 2000 and 2002.
  • At 1 year after the operation, bladder symptoms were significantly improved in the nerve-sparing group compared to the non-nerve-sparing group.
  • Urinary incontinence and abnormal (diminished) bladder sensation were observed in three of the five patients (two patients had both symptoms), for whom the nerve-sparing procedure could not be performed, but none of the 22 patients for whom the nerve-sparing procedure was performed had incontinence, and only two patients had abnormal (increased) bladder sensation (P= 0.0034 for incontinence and P= 0.030 for abnormal bladder sensation).
  • The patients' survival was not adversely affected by the nerve-sparing procedure.
  • Although it is still preliminary, the surgical technique described in this report is thought to be effective for preserving bladder function, and thus, the quality of life could be improved for patients with cervical cancer who are treated with a radical hysterectomy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Hysterectomy / methods. Neoplasm Invasiveness. Postoperative Complications / prevention & control. Urinary Bladder / innervation. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Neoplasm Staging. Quality of Life. Splanchnic Nerves / injuries. Splanchnic Nerves / physiology. Survival Analysis. Treatment Outcome. Urinary Incontinence / etiology. Urinary Incontinence / prevention & control


10. Marques ML, D'Alessandro GS, Chade DC, Lanzoni VP, Saiovici S, Almeida CJ: Primary mucinous adenocarcinoma of the bladder with signet-ring cells: case report. Sao Paulo Med J; 2007 Sep 6;125(5):297-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma of the bladder with signet-ring cells: case report.
  • CONTEXT: Primary adenocarcinomas of the bladder are uncommon and usually occur by contiguity with or hematogenic dissemination of other adenocarcinomas such as colorectal, prostate and gynecological tract carcinomas.
  • Mucinous and signet-ring cell histological patterns are even rarer and it is often difficult to morphologically distinguish them from metastatic colorectal adenocarcinoma.
  • CASE REPORT: We present and discuss a rare case of primary mucinous adenocarcinoma of the bladder with signet-ring cells in a 57-year-old male patient.
  • Other primary sites for the tumor had been excluded and, in the absence of digestive tract tumor and for confirmation that it was a primary bladder tumor, an immunohistochemistry study was performed.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Signet Ring Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Humans. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Mucin-2. Mucins / analysis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094900.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


11. Kösem M, Sengül E: Clear cell adenocarcinoma of the urinary bladder. Scand J Urol Nephrol; 2005;39(1):89-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the urinary bladder.
  • Clear cell adenocarcinoma of the lower urinary tract, and particularly of the bladder, is a rare neoplasm and its histogenesis remains obscure.
  • The authors report the clinical and pathologic findings of a 55-year-old male with clear cell carcinoma of the bladder.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Urinary Bladder Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764280.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Sweden
  • [Number-of-references] 15
  •  go-up   go-down


12. Constantinides C, Haritopoulos K, Anastasiou I, Dritsas C, Papamichael V, Zervas A: Multiple metastases of prostatic adenocarcinoma to the urethra after radical prostatectomy. Urol Int; 2007;79(1):92-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple metastases of prostatic adenocarcinoma to the urethra after radical prostatectomy.
  • We present a rare case of multiple metastases of a prostatic adenocarcinoma to the urethra.
  • Radical prostatectomy had been performed 13 years before, and during this time he had been frequently treated with transurethral resections of the bladder neck for obstructive urinary symptoms.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Urethral Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627178.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Somoye GO, Gull S: Adenocarcinoma of the vaginal vault following prolonged unopposed oestrogen hormone replacement therapy. J Obstet Gynaecol; 2005 Feb;25(2):220-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the vaginal vault following prolonged unopposed oestrogen hormone replacement therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Estradiol / adverse effects. Estrogen Replacement Therapy / adverse effects. Urinary Bladder Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Endometriosis. Female. Humans

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814421.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 4TI98Z838E / Estradiol
  •  go-up   go-down


14. Blank LE, Koedooder K, van Os R, van de Kar M, van der Veen JH, Koning CC: Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):454-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter.
  • PURPOSE: To evaluate the long-term, local relapse-free, distant metastasis-free, and overall survival rates in patients with a solitary bladder tumor <5 cm in diameter who were treated with external beam radiotherapy, limited surgery, and brachytherapy.
  • METHODS AND MATERIALS: The results of 122 patients after bladder-saving treatment were analyzed.
  • CONCLUSION: The results of our study have shown that external beam radiotherapy followed by brachytherapy as a bladder-saving treatment for a selected group of patients with bladder cancer yields excellent local tumor control and low toxicity.
  • [MeSH-major] Brachytherapy / methods. Cystectomy. Urinary Bladder Neoplasms / radiotherapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Combined Modality Therapy / methods. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Radiotherapy Dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560734.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Agaimy A, Pelz AF, Wieacker P, Roessner A, Wünsch PH, Schneider-Stock R: Gastrointestinal stromal tumors of the vermiform appendix: clinicopathologic, immunohistochemical, and molecular study of 2 cases with literature review. Hum Pathol; 2008 Aug;39(8):1252-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only 5 cases have been reported so far, all being 14 mm or less, and they have yet not been investigated at the molecular level.
  • Here, we report 2 appendiceal gastrointestinal stromal tumors in a 78-year-old woman and a 72-year-old man with a history of endometrial adenocarcinoma and urinary bladder carcinoma, respectively.
  • Both gastrointestinal stromal tumors were incidental findings at surgery for appendicitis-like symptoms and on follow-up for bladder carcinoma, respectively.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18547614.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 21
  •  go-up   go-down


16. Vandecasteele K, De Neve W, De Gersem W, Delrue L, Paelinck L, Makar A, Fonteyne V, De Wagter C, Villeirs G, De Meerleer G: Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation. Strahlenther Onkol; 2009 Dec;185(12):799-807
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.
  • Dose constraints on D(50) were not met in two patients (both GTV_cervix: 1 Gy and 3 Gy less).
  • D(98) for PTV_nodes was not met in three patients (1 Gy each).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cervix Uteri / radiation effects. Dose Fractionation. Female. Film Dosimetry. Humans. Image Processing, Computer-Assisted. Intestines / radiation effects. Lymphatic Irradiation. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Positron-Emission Tomography. Quality Control. Radiotherapy Dosage. Tomography, X-Ray Computed. Urinary Bladder / radiation effects

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • [Cites] Phys Med Biol. 2004 Jan 21;49(2):287-305 [15083672.001]
  • [Cites] Strahlenther Onkol. 2008 Sep;184(9):473-7 [19016026.001]
  • [Cites] Am J Obstet Gynecol. 2007 Nov;197(5):503.e1-6 [17980189.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225 [16034873.001]
  • [Cites] Strahlenther Onkol. 2009 May;185(5):282-7 [19440666.001]
  • [Cites] J Nucl Med. 2005 Nov;46(11):1842-50 [16269598.001]
  • [Cites] Cancer Radiother. 2002 Nov;6 Suppl 1:32s-36s [12587381.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):933-9 [15936580.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1330-7 [11955746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):794-806 [15465196.001]
  • [Cites] Strahlenther Onkol. 2007 Sep;183(9):487-9 [17762922.001]
  • [Cites] Radiother Oncol. 2003 Sep;68(3):217-26 [13129628.001]
  • [Cites] Radiother Oncol. 2005 Sep;76(3):340-53 [16099521.001]
  • [Cites] Radiat Oncol. 2006 May 04;1:13 [16722546.001]
  • [Cites] Radiother Oncol. 2007 May;83(2):148-55 [17531904.001]
  • [Cites] Gynecol Oncol. 1993 Jun;49(3):311-7 [8314532.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1371-88 [11728699.001]
  • [Cites] Radiother Oncol. 2007 Aug;84(2):156-63 [17692976.001]
  • [Cites] Gynecol Oncol. 2006 Sep;102(3):523-9 [16504274.001]
  • [Cites] Strahlenther Onkol. 2005 Jul;181(7):424-30 [15995835.001]
  • [Cites] Gynecol Oncol. 1994 Jul;54(1):68-75 [8020842.001]
  • [Cites] Semin Radiat Oncol. 2002 Jul;12(3):260-71 [12118391.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1019-32 [14575833.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183 Spec No 2:19-20 [18167001.001]
  • [Cites] Strahlenther Onkol. 2005 Aug;181(8):483-99 [16044216.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(1):47-9 [16550968.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):373-9 [10684713.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1062-70 [15752885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):830-41 [15708263.001]
  • [Cites] Strahlenther Onkol. 2009 Mar;185(3):177-83 [19330295.001]
  • [Cites] Eur J Surg Oncol. 2008 May;34(5):569-75 [17531428.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):95-100 [1993635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):261-6 [11516876.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):182-8 [16516281.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):343-53 [12798694.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):324-8 [10985888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1257-80 [7713787.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2804-10 [17502627.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Feb;18(1):38-45 [16477918.001]
  • [Cites] Med Phys. 1998 May;25(5):656-61 [9608475.001]
  • [Cites] Phys Med Biol. 2007 Jan 7;52(1):231-42 [17183138.001]
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):586-91 [19016017.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Jun;14(3):203-12 [12109823.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1438-44 [17394944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1604-12 [16198509.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):471-88 [14585258.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):498-503 [17156969.001]
  • (PMID = 20013089.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Azuma H, Yamamoto K, Inamoto T, Ibuki N, Kotake Y, Sakamoto T, Kiyama S, Ubai T, Takahara K, Segawa N, Narumi Y, Katsuoka Y: Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Am J Clin Oncol; 2009 Dec;32(6):592-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
  • OBJECTIVES: We tested the usefulness of balloon-occluded arterial infusion (BOAI) of anticancer agent (cisplatin/gemcitabine), concomitant with hemodialysis, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects, along with concurrent radiation [Osaka-Medical College (OMC)-regimen] in patients with locally advanced bladder cancer.
  • CONCLUSION: OMC-regimen, a new strategy for patients with locally-invasive bladder cancer, can be curative not only in patients for whom cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative treatment would otherwise seem the only option.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Balloon Occlusion. Cisplatin / administration & dosage. Cystectomy. Renal Dialysis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Choriocarcinoma / secondary. Choriocarcinoma / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Middle Aged. Muscle Neoplasms / secondary. Muscle Neoplasms / therapy. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593084.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Hayashi T, Ujike T, Yamamoto Y, Kamoto A, Nin M, Nishimura K, Miyoshi S, Kawano K: [Female urethral adenocarcinoma with urinary retention: a case report]. Hinyokika Kiyo; 2009 Jul;55(7):429-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Female urethral adenocarcinoma with urinary retention: a case report].
  • A 57-year-old woman presented with urinary retention.
  • Intravenous pyelography demonstrated the filling defect of bladder.
  • Magnetic resonance imaging revealed the mass that had invaded bladder neck at dorsal side of urethra.
  • Pathological examination of transvaginal needle biopsy suggested well-differentiated adenocarcinoma.
  • Pathological diagnosis was urethral adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Urethral Neoplasms / complications. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673433.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


19. Hussein K, Nanda A, Al-Sabah H, Alsaleh QA: Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder. J Eur Acad Dermatol Venereol; 2005 Sep;19(5):597-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder.
  • In the present report, we describe an 82-year-old male with SS in association with adenocarcinoma of the prostate and transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Neoplasms, Multiple Primary / diagnosis. Prostatic Neoplasms / pathology. Sweet Syndrome / diagnosis. Urinary Bladder Neoplasms / pathology


20. Tanaka H, Masuda H, Komai Y, Yokoyama M, Iwai A, Numao N, Sakai Y, Saito K, Fujii Y, Kobayashi T, Kawakami S, Kihara K: [Primary adenocarcinoma of the female urethra treated by multimodal therapy]. Hinyokika Kiyo; 2009 Jan;55(1):43-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the female urethra treated by multimodal therapy].
  • A 64-year old female presented with urinary retention.
  • Pathological examinations of the transurethral and transvaginal needle biopsy specimen suggested mucinous adenocarcinoma.
  • Then she underwent total cysto-urethrectomy with anterior vaginal wall resection, pelvic lymphadenectomy, and urinary diversion with ureterocutaneous fistula.
  • Histopathological examination of the surgical specimen showed mutinous adenocarcinoma invading to the vesical triangle and the anterior vaginal wall.
  • The final diagnosis was urethral adenocarcinoma, pT4N0, Stage IV.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227213.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Egevad L, Håkansson U, Grabe M, Ehrnstrom R: Urachal signet-cell adenocarcinoma. Scand J Urol Nephrol; 2009;43(1):88-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal signet-cell adenocarcinoma.
  • This report presents two cases of urachal signet-cell adenocarcinoma (USCA).
  • Cystoscopy showed tumours in the dome of the bladder and transurethral resection revealed signet ring cell carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / metabolism. Urachus. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759168.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Keratin-20
  •  go-up   go-down


22. Smith AK, Hansel DE, Jones JS: Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. Urology; 2008 May;71(5):915-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma.
  • OBJECTIVES: Cystitis cystica et glandularis (CCEG) and intestinal metaplasia (IM) have been suggested to represent precursors of bladder adenocarcinoma.
  • The relationship between these entities and the subsequent development of bladder carcinoma remains unclear.
  • METHODS: We retrospectively evaluated the association among florid CCEG, IM, and bladder carcinoma.
  • The records and imaging findings of patients with a pathologic diagnosis of florid CCEG and/or IM were reviewed for a concurrent or future diagnosis of bladder carcinoma or pelvic lipomatosis.
  • Of the 117 patients with CCEG, a subset was identified with concurrent mucinous adenocarcinoma (n = 1; <1%), squamous cell carcinoma (n = 4; 3%), or urothelial carcinoma (n = 34; 29%) at diagnosis.
  • Pure IM was identified concurrently with adenocarcinoma in 2 (10%), urothelial carcinoma in 4 (21%), and urothelial carcinoma with glandular differentiation in 1 (5%) of 19 patients.
  • CONCLUSIONS: Both florid CCEG and IM can be identified in benign bladder specimens or in conjunction with bladder carcinoma.
  • Although IM can be associated with a concurrent diagnosis of carcinoma, we found no evidence that it increases the future risk of malignancy and our findings do not support a recommendation for surveillance cystoscopy in such patients.
  • [MeSH-major] Cystitis / complications. Intestines / pathology. Precancerous Conditions / pathology. Urinary Bladder Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455631.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kim SY, Oh YL, Kim KM, Jeong EG, Kim MS, Yoo NJ, Lee SH: Decreased expression of Bax-interacting factor-1 (Bif-1) in invasive urinary bladder and gallbladder cancers. Pathology; 2008 Oct;40(6):553-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of Bax-interacting factor-1 (Bif-1) in invasive urinary bladder and gallbladder cancers.
  • AIMS: Mounting evidence indicates that deregulation of apoptosis is involved in the mechanisms of cancer development.
  • The aim of this study was to explore whether loss of Bif-1 expression occurs in urinary bladder (UB) and gallbladder (GB) cancer tissues.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / biosynthesis. Adenocarcinoma / metabolism. Carcinoma, Transitional Cell / metabolism. Gallbladder Neoplasms / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752120.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / SH3GLB1 protein, human
  •  go-up   go-down


24. Su A, Reft C, Rash C, Price J, Jani AB: A case study of radiotherapy planning for a bilateral metal hip prosthesis prostate cancer patient. Med Dosim; 2005;30(3):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case study of radiotherapy planning for a bilateral metal hip prosthesis prostate cancer patient.
  • Using the same target expansions for each phase, IMRT and 3D-conformal radiotherapy (CRT) plans were compared for target coverage and inhomogeneity as well as dose to the bladder and rectum.
  • Similarly, the dose to the bladder was significantly reduced with a V 80 of 9% versus 20%.
  • Overall, various dosimetric parameters revealed the corresponding 3D-CRT plan would not have been acceptable.
  • Therefore, definitive external beam radiation of prostate cancer patients with bilateral prosthesis is made feasible with IMRT.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Hip Prosthesis. Prostatic Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Aged. Humans. Male. Metals. Prostate / radiation effects. Radiotherapy Dosage. Rectum / radiation effects. Urinary Bladder / radiation effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112469.001).
  • [ISSN] 0958-3947
  • [Journal-full-title] Medical dosimetry : official journal of the American Association of Medical Dosimetrists
  • [ISO-abbreviation] Med Dosim
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


25. Domanowska E, Jozwicki W, Domaniewski J, Golda R, Skok Z, Wiśniewska H, Sujkowska R, Wolski Z, Jozwicka G: Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol; 2007 May;38(5):741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize.
  • Few published studies have addressed the correlation between multidirectional differentiation in muscle-invasive bladder cancer and its ability to metastasize.
  • We examined cystectomy specimens from 93 bladder tumors and 1085 lymph nodes.
  • In this study, urothelial cell carcinomas (UCCs) with divergent differentiation, excluding pure divergent patterns such as squamous cell carcinoma and adenocarcinoma that tend toward a distinct biologic behavior, were subjected to histopathologic estimation.
  • [MeSH-major] Cell Differentiation. Muscles / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306328.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Wilhelm TJ, Knoll T, Weisser G, Grobholz R, Köhrmann KU, Post S: Urothelial carcinoma of the ureter, giant rectal stone and sigmoid carcinoma 55 years after ureterosigmoidostomy. Scand J Urol Nephrol; 2006;40(2):172-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a unique accumulation of complications 55 years after ureterosigmoidostomy for bladder exstrophy and discuss possible implications for follow-up strategies.
  • [MeSH-major] Calculi / pathology. Colonic Neoplasms / pathology. Rectal Diseases / pathology. Ureteral Neoplasms / pathology. Urinary Bladder / abnormalities. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Humans. Ileum / surgery. Male. Middle Aged. Reconstructive Surgical Procedures. Sigmoidoscopy. Tomography, X-Ray Computed. Ureterostomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608820.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


27. Lum D: Clear cell carcinoma of the urinary bladder. Pathology; 2006 Aug;38(4):367-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoembryonic Antigen / genetics. Carcinoembryonic Antigen / metabolism. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Keratins / genetics. Keratins / metabolism. Male. Membrane Proteins / genetics. Membrane Proteins / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916733.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Carcinoembryonic Antigen; 0 / Membrane Proteins; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


28. Keiler L, Dobbins D, Kulasekere R, Einstein D: Tomotherapy for prostate adenocarcinoma: a report on acute toxicity. Radiother Oncol; 2007 Aug;84(2):171-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tomotherapy for prostate adenocarcinoma: a report on acute toxicity.
  • BACKGROUND AND PURPOSE: To analyze the impact of Tomotherapy (TOMO) intensity modulated radiotherapy (IMRT) on acute gastrointestinal (GI) and genitourinary (GU) toxicity in prostate cancer.
  • In univariate analysis, androgen deprivation, prostate volume, pre-treatment urinary toxicity, and prostate dose homogeneity correlated with acute GI and GU toxicity.
  • With multivariate analysis use of Tomotherapy, median bladder dose and bladder dose homogeneity remained significantly correlated with GU toxicity.
  • CONCLUSIONS: Acute GI toxicity for prostate cancer is improved with Tomotherapy at a cost of increased acute GU toxicity possibly due to differences in bladder and prostate dose distribution.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Prostate / drug effects. Radiotherapy Dosage. Urinary Bladder / drug effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692975.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


29. Hu SC, Chen GS, Wu CS, Chai CY, Chen WT, Lan CC: Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. J Am Acad Dermatol; 2009 Mar;60(3):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the rate of cutaneous metastasis from breast cancer was much lower compared with previous studies involving Caucasians.
  • In addition, the expressions of CCR10 and CXCR4 by tumor cells did not correlate well with the presence or absence of skin metastases.
  • [MeSH-major] Adenocarcinoma / ethnology. Adenocarcinoma / secondary. Breast Neoplasms / ethnology. Breast Neoplasms / pathology. Skin Neoplasms / ethnology. Skin Neoplasms / secondary
  • [MeSH-minor] Academic Medical Centers / statistics & numerical data. Asian Continental Ancestry Group / statistics & numerical data. Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / secondary. Carcinoma, Squamous Cell / ethnology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / ethnology. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / secondary. Gastrointestinal Neoplasms / ethnology. Gastrointestinal Neoplasms / metabolism. Gastrointestinal Neoplasms / pathology. Humans. Immunohistochemistry. Liver Neoplasms / ethnology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lung Neoplasms / ethnology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Mouth Neoplasms / ethnology. Mouth Neoplasms / metabolism. Mouth Neoplasms / pathology. Receptors, CCR10 / metabolism. Receptors, CXCR4 / metabolism. Retrospective Studies. Taiwan / epidemiology. Urinary Bladder Neoplasms / ethnology. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056145.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR10 protein, human; 0 / CXCR4 protein, human; 0 / Receptors, CCR10; 0 / Receptors, CXCR4
  •  go-up   go-down


30. Sterk P, Shekarriz B, Günter S, Nolde J, Keller R, Bruch HP, Shekarriz H: Voiding and sexual dysfunction after deep rectal resection and total mesorectal excision: prospective study on 52 patients. Int J Colorectal Dis; 2005 Sep;20(5):423-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Postoperatively, we sought first to determine the frequency of a urinary or sexual dysfunction, secondly whether there is a time-dependent change of a dysfunction and thirdly whether there is a relationship between postoperative urological dysfunction and the patient's age.
  • RESULTS: Urological dysfunction: Preoperatively, 49 of the 52 patients had a completely normal bladder function and three patients had post void residual >100 ml.
  • Postoperatively, 12 of the 49 patients with normal preoperatively urinary function had voiding dysfunction, but only four male patients had residual urine in the third postoperative month.
  • Therefore, in about 90% of the patients, postoperative bladder function became normal and only 10% suffered from vesical denervation after 6 months.
  • We could not determine a relationship between the degree of bladder dysfunction and the patient's age due to a relatively small patient cohort in this study.
  • Eleven men specified a limited erection, but all had occasional sexual intercourse.
  • Although it is likely that the potency may diminish with advanced age, the incidence of impotence was not higher in the older patients of our study.
  • Of patients with postoperative bladder dysfunction, 90% improved within 6 months after surgery and only 10% continued to have bladder dysfunction beyond 6 months, indicating irreversible nerve damage.
  • [MeSH-major] Adenocarcinoma / physiopathology. Adenocarcinoma / surgery. Coitus. Digestive System Surgical Procedures / adverse effects. Rectal Neoplasms / physiopathology. Rectal Neoplasms / surgery. Urination

  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chirurg. 1989 Apr;60(4):228-34 [2721301.001]
  • [Cites] Br J Surg. 1983 Aug;70(8):460-2 [6871635.001]
  • [Cites] Urologe A. 1984 Nov;23(6):324-8 [6542708.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1988;114:5-19 [3201169.001]
  • [Cites] Br J Urol. 1995 Dec;76(6):752-6 [8535720.001]
  • [Cites] Br J Surg. 1998 Jan;85(1):92-7 [9462393.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10):1140-5 [8831531.001]
  • [Cites] J Am Coll Surg. 1996 Jun;182(6):495-502 [8646349.001]
  • [Cites] Urol Int. 1991;46(3):259-65 [1926639.001]
  • [Cites] Urol Int. 1985;40(1):60-4 [3976090.001]
  • [Cites] Langenbecks Arch Surg. 1999 Apr;384(2):167-75 [10328170.001]
  • [Cites] Ann Surg. 1980 Jan;191(1):81-6 [7352782.001]
  • [Cites] Ann Chir Gynaecol. 1988;77(2):51-6 [3232948.001]
  • [Cites] Dis Colon Rectum. 1994 Feb;37(2 Suppl):S42-6 [8313791.001]
  • (PMID = 15846498.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Black PC, Brown GA, Dinney CP: The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol; 2009 Jan-Feb;27(1):3-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of variant histology on the outcome of bladder cancer treated with curative intent.
  • Patient risk stratification is essential for optimal management of patients with bladder cancer.
  • One key factor in such risk stratification appears to be the presence of variant histologic patterns in the bladder tumor.
  • More than 90% of tumors are conventional urothelial carcinoma, and the rest consist of urothelial carcinoma with aberrant differentiation (squamous/glandular differentiation, small cell carcinoma, sarcomatoid carcinoma, and micropapillary carcinoma) or nonurothelial carcinoma (squamous cell carcinoma and adenocarcinoma).
  • In this review, we focus on the implications of aberrant differentiation on the management of patients with bladder cancer.
  • Although radical cystectomy remains the mainstay of treatment in all forms of bladder cancer, we highlight the use of neoadjuvant chemotherapy in patients with subtypes responsive to such therapy.
  • [MeSH-major] Medical Oncology / methods. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367107.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA91846; United States / PHS HHS / / T32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


32. Kondo T: Bile duct adenocarcinoma with minor micropapillary component: a case report. Cases J; 2009;2(1):51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile duct adenocarcinoma with minor micropapillary component: a case report.
  • This histologic pattern has been described in various organs, including the breast, lung, urinary bladder, ovary, stomach, pancreas, and major salivary glands.
  • Here a case of bile duct adenocarcinoma with minor micropapillary component is described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2008 Aug;53(8):2287-9 [18224441.001]
  • [Cites] Pancreas. 2007 Aug;35(2):190-2 [17632330.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):809-15 [16784979.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1504-11 [16007065.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1224-32 [7977945.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):319-26 [15104294.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • (PMID = 19144165.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2639564
  •  go-up   go-down


33. Kwiatkowski M, Paśnik K, Orłowski M, Furga P: [Therapeutic and diagnostic problems in a patient with a pelvic tumour--case report]. Pol Merkur Lekarski; 2009 May;26(155):496-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer has become the commonest form of cancer in gastrointestinal (GI) tract and nowadays it is the second cause of death among all malignant tumours.
  • Bladder cancer is the fourth commonest tumour in males and eighth in females.
  • Despite repeated colon and bladder biopsies no malignancy was found.
  • The results of imaging investigations suggested a bladder-derived tumour (from a bladder diverticulum or persisting urachus).
  • The diagnosis confirmed in histological examination was adenocarcinoma of the colon.
  • The article presents successive stages of diagnosis and therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Humans. Male. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606709.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


34. Chura JC, Brooker D, Downs LS Jr: Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature. Gynecol Oncol; 2006 Oct;103(1):336-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature.
  • BACKGROUND: Carcinoma of the urinary bladder that occurs after urinary diversion is a rare entity.
  • We report a case of an adenocarcinoma arising in a defunctionalized bladder that presented as locally advanced endometrial carcinoma.
  • She had a prior history of urinary diversion via a Koch pouch.
  • Examination revealed a mass protruding through the cervix and possibly involving the bladder anteriorly.
  • The patient underwent anterior pelvic exenteration for a locally advanced mucinous carcinoma thought to be arising from the uterus and invading into the bladder.
  • Final pathology, however, was consistent with a primary bladder carcinoma.
  • CONCLUSION: Carcinoma developing in the bladder after urinary diversion presents at an advanced stage and has associated poor overall survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Urinary Diversion / adverse effects

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793125.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Pearce A, Reid C, Gramp A, Sidhu S: A 30-year history of CD4+ vesiculo-bullous mycosis fungoides and multiple visceral malignancies. Australas J Dermatol; 2007 Feb;48(1):46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had a past history of adenocarcinoma of the lung, colorectal carcinoma and bladder carcinoma.
  • Direct and indirect immunofluorescence studies were repeatedly negative, excluding the possibility of an autoimmune blistering disorder.
  • [MeSH-major] Antigens, CD4. Mycosis Fungoides / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / complications. Administration, Cutaneous. Aged. Aged, 80 and over. Betamethasone / analogs & derivatives. Betamethasone / therapeutic use. Carcinoma, Transitional Cell / complications. Colorectal Neoplasms / complications. Diagnosis, Differential. Female. Humans. Lung Neoplasms / complications. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BETAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222304.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD4; 826Y60901U / betamethasone-17,21-dipropionate; 9842X06Q6M / Betamethasone
  •  go-up   go-down


36. Datta C, Bhattacharyya S, Bhattacharya S, Ghosh S: Primary adenocarcinoma of bladder--A case report. J Indian Med Assoc; 2006 Jun;104(6):338-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of bladder--A case report.
  • Ultrasonography depicted an echogenic mass on bladder wall, where prostate showed normal echo characters.
  • Cystoscopy revealed a large papillary growth involving lateral wall, neck of the urinary bladder and prostatic urethra.
  • Punched biopsy showed features of adenocarcinoma.
  • Radical cystectomy was performed and it was reported as a case of primary adenocarcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058556.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


37. Parikh B, Trivedi P, Ohri A, Shukla K, Desai S: Primary mucinous carcinoma of urachus--a case report. Indian J Pathol Microbiol; 2006 Jul;49(3):409-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Urachus. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001902.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


38. Bollito ER, Pacchioni D, Lopez-Beltran A, Volante M, Terrone C, Casetta G, Mari M, DePompa R, Cappia S, Papotti M: Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder. Anal Quant Cytol Histol; 2005 Aug;27(4):218-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder.
  • OBJECTIVE: Neuroendocrine (NE) cells are uncommon in primary adenocarcinoma (AC) and other glandular lesions of the bladder, with no recent study series concerning its significance in differential diagnosis, prognosis or biologic significance.
  • STUDY DESIGN: Sixteen primary bladder AC (enteric-type [n = 71, mucinous [n = 6] and not otherwise specified [NOS] [n = 31), 4 cases of urothelial carcinoma with glandular differentiation, 20 cases of glandular cystitis and 3 urachal remnants with intestinal metaplasia constituted the study series.
  • RESULTS: Chromogranin A-positive cells were present in 60% (11 of 16) of primary AC, all of enteric or mucinous type, but not in any of the 3 NOS-type AC investigated.
  • NE differentiation in bladder AC subtypes resulted in highly significant differences between enteric or mucinous vs. NOS type (p = 0.0023).
  • NE differentiation was also different in urachal vs. nonurachal AC (p = 0.020) and primary bladder AC vs. conventional invasive urothelial carcinoma (p < 0.001).
  • Synaptophysin-positive cells were seen in 2 (12.5%) of the 16 primary AC cases, and NSE was negative in the 16 primary bladder AC.
  • One of 4 urothelial carcinomas with glandular differentiation had chromogranin A-immunoreactive cells, but this was not significant when compared with primary AC (p = 0.1).
  • Normal-looking bladder urothelium and conventional urothelial carcinoma specimens had no chromogranin A-immunoreactive cells.
  • No correlation was found between NE differentiation and outcome of primary bladder AC or urothelial carcinoma with glandular differentiation.
  • CONCLUSION: Primary bladder AC, cystitis glandularis and urachal remnants with intestinal metaplasia showed variable degrees of NE differentiation, with no apparent clinical correlation or prognostic significance.
  • However, the absence of NE differentiation in NOS-type primary bladder AC may help in better defining this uncommon subtype of primary bladder AC.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220833.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


39. Pouessel D, Huguet H, Iborra F, Rebillard X, Ayuso D, Becht C, Culine S: A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer. Anticancer Res; 2010 Nov;30(11):4711-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
  • AIM: To assess the safety and to obtain preliminary data on the efficacy of the three-drug combination chemotherapy with gemcitabine, oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
  • PATIENTS AND METHODS: Patients with metastatic or locally unresectable advanced bladder cancer who had received either no or one previous systemic chemotherapy regimen were eligible.
  • Further clinical trials are not recommended.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115929.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


40. Wright JL, Porter MP, Li CI, Lange PH, Lin DW: Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer; 2006 Aug 15;107(4):721-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder.
  • BACKGROUND: Primary adenocarcinomas of the bladder and urachus are rare malignancies, and knowledge of the patient demographics, pathologic characteristics, and survival associated with these tumors is poor.
  • The current study compares disease-specific characteristics and survival associated with urachal and nonurachal primary bladder adenocarcinomas.
  • METHODS: Incident cases of urachal and nonurachal primary adenocarcinomas of the bladder were identified from the Surveillance, Epidemiology, and End Results (SEER) Program.
  • Demographic and pathologic characteristics at the time of diagnosis were compared.
  • Risks of mortality among urachal and nonurachal primary adenocarcinomas of the bladder were compared using multivariate Cox regression.
  • RESULTS: A total of 151 urachal and 1374 nonurachal adenocarcinomas of the bladder patients were identified.
  • Compared to those with nonurachal tumors, patients with urachal adenocarcinoma were more likely to be younger (median age, 56 vs. 69 years, P <.0001) and female (45% vs. 36%, P = .02).
  • CONCLUSIONS. Urachal adenocarcinomas represent 10% of all primary adenocarcinomas of the bladder.
  • [MeSH-major] Adenocarcinoma / mortality. Urachus. Urinary Bladder Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826584.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Lane Z, Hansel DE, Epstein JI: Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol; 2008 Sep;32(9):1322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
  • Adenocarcinomas of the bladder are rare, with the diagnosis dependent on exclusion of secondary involvement by direct extension or metastatic spread from other sites.
  • The recent description of an unusual form of urothelial-type mucinous prostatic adenocarcinoma raises a novel differential diagnosis between adenocarcinomas of the prostate and bladder, and investigation into the utility of classic prostatic immunohistochemical antigens in bladder adenocarcinoma is warranted.
  • We identified 37 primary infiltrating adenocarcinomas of the bladder, which included signet ring cell carcinomas (n=11), urachal adenocarcinomas (n=5), and enteric adenocarcinoma (n=21).
  • Also included for comparison were 3 cases, each of bladder villous adenomas and bladder adenocarcinoma in situ.
  • In contrast, a minority of bladder adenocarcinomas was labeled with the prostate antigens P501S and PSMA.
  • P501S showed moderate diffuse cytoplasmic staining in 4/37 cases (11%), including 3 enteric-type adenocarcinomas and 1 mucinous adenocarcinoma.
  • Additionally, 1 case of adenocarcinoma in situ demonstrated diffuse cytoplasmic staining for P501S.
  • The granular perinuclear staining pattern of P501S typically seen in prostatic adenocarcinoma was absent in all cases of bladder adenocarcinoma.
  • PSMA showed diffuse cytoplasmic staining in 4/37 (11%) infiltrating adenocarcinomas (including 1 signet ring carcinoma and 3 enteric-type adenocarcinomas), and in 1 case of adenocarcinoma in situ.
  • Membranous PSMA staining was evident in an additional 3 tumors, 1 urachal mucinous adenocarcinoma, 1 nonurachal mucinous and signet ring cell adenocarcinoma, and 1 nonurachal villous adenoma.
  • In conclusion, although all cases of bladder adenocarcinoma examined were negative for PSA and PSAP, the surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenocarcinomas.
  • The lack of granular perinuclear staining for P501S and the absence of membranous PSMA staining both favor a bladder adenocarcinoma, although rare cases of villous adenoma and adenocarcinoma did show PSMA membranous staining indistinguishable from that seen in prostate cancer.
  • Although the novel antigens P501S and PSMA are fairly specific and more sensitive in the differential diagnosis of prostate and urothelial carcinoma, care must be taken when adenocarcinomas of the bladder are considered within this differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Antigens, Neoplasm / biosynthesis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Acid Phosphatase. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Membrane Proteins / biosynthesis. Prostate-Specific Antigen / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Protein Tyrosine Phosphatases / biosynthesis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670358.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Membrane Proteins; 0 / prostein; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


42. Pekáriková A, Sánchez D, Palová-Jelínková L, Simsová M, Benes Z, Hoffmanová I, Drastich P, Janatková I, Mothes T, Tlaskalová-Hogenová H, Tucková L: Calreticulin is a B cell molecular target in some gastrointestinal malignancies. Clin Exp Immunol; 2010 May;160(2):215-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using enzyme-linked immunosorbent assay (ELISA), we found immunoglobulin (Ig)A and/or IgG anti-calreticulin antibodies in sera of approximately 63% of patients with hepatocellular carcinoma (HCC), 57% of patients with colorectal adenocarcinoma (CRA) and 47% of patients with pancreatic adenocarcinoma (PACA), while healthy controls, patients with viral hepatitis C and with chronic pancreatitis reached only 2%, 20% and 31% seropositivity, respectively.
  • Significantly elevated mean levels of IgG anti-calreticulin antibodies (P < 0.001) were detected in patients with HCC (121.9 +/- 94.2 AU), gall bladder adenocarcinoma (118.4 +/- 80.0 AU) and PACA (88.7 +/- 55.6 AU) when compared to healthy controls (56.7 +/- 22.9 AU).
  • [MeSH-major] Adenocarcinoma / immunology. Antibodies, Neoplasm / immunology. Autoantibodies / immunology. Autoantigens / immunology. B-Lymphocytes / immunology. Calreticulin / immunology. Carcinoma, Hepatocellular / immunology. Colorectal Neoplasms / immunology. Liver Neoplasms / immunology. Neoplasm Proteins / immunology. Pancreatic Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2009 Mar;15(1):89-90 [18925427.001]
  • [Cites] Biochem J. 2009 Feb 1;417(3):651-66 [19133842.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1117-20 [10706133.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):1056-61 [10763959.001]
  • [Cites] J Autoimmun. 2000 Dec;15(4):441-9 [11090243.001]
  • [Cites] J Clin Invest. 2001 Nov;108(10):1411-5 [11714730.001]
  • [Cites] Mol Cell Proteomics. 2002 Mar;1(3):197-203 [12096119.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43 [12582023.001]
  • [Cites] Clin Chem. 2003 Jul;49(7):1206-8 [12816927.001]
  • [Cites] Clin Exp Immunol. 2003 Oct;134(1):143-50 [12974767.001]
  • [Cites] J Autoimmun. 2003 Dec;21(4):383-92 [14624761.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5504-10 [15289361.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):1149-55 [15375567.001]
  • [Cites] J Mol Biol. 1973 Nov 15;80(4):575-99 [4204102.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):942-3 [9797714.001]
  • [Cites] Hybridoma. 1998 Oct;17(5):431-5 [9873988.001]
  • [Cites] J Exp Med. 1999 Mar 1;189(5):797-802 [10049943.001]
  • [Cites] Scand J Immunol. 1999 May;49(5):466-73 [10320638.001]
  • [Cites] Hum Immunol. 1999 Jun;60(6):510-5 [10408800.001]
  • [Cites] Cancer Detect Prev. 2005;29(3):241-8 [15896923.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):187-98 [16297705.001]
  • [Cites] Nat Med. 2007 Jan;13(1):54-61 [17187072.001]
  • [Cites] Nat Biotechnol. 2007 Feb;25(2):192-3 [17287754.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):209-16 [17276050.001]
  • [Cites] Expert Opin Biol Ther. 2007 Apr;7(4):493-507 [17373901.001]
  • [Cites] Tissue Antigens. 2007 Jul;70(1):1-11 [17559575.001]
  • [Cites] Immunol Rev. 2007 Dec;220:22-34 [17979837.001]
  • [Cites] J BUON. 2008 Jan-Mar;13(1):101-7 [18404795.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2476-83 [18413840.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3830-7 [18683965.001]
  • [Cites] Clin Exp Immunol. 2008 Sep;153(3):351-9 [18637103.001]
  • [Cites] Cancer Lett. 2009 Aug 18;281(1):8-23 [19091462.001]
  • (PMID = 20030668.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Autoantibodies; 0 / Autoantigens; 0 / Calreticulin; 0 / Epitopes; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2857944
  •  go-up   go-down


43. Lee JI: Micropapillary carcinoma of the urinary bladder: a case report. Acta Cytol; 2009 May-Jun;53(3):344-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary carcinoma of the urinary bladder: a case report.
  • Urine cytology contained tight clusters of atypical cells, originally interpreted as high-grade urothelial carcinoma or adenocarcinoma.
  • Final diagnosis was made by histology and immunohistochemical study.
  • Careful cytologic examination in combination with cell block morphology and immunohistochemistry may allow early accurate diagnosis and appropriate management.
  • [MeSH-major] Carcinoma, Papillary / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534282.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Mucin-1
  •  go-up   go-down


44. Samper Ots PM, López Carrizosa C, Rodríguez A, de Dios Sáez J, Delgado JM, Martín de Miguel M, Vidal M: Vesical instillations of hyaluronic acid to reduce the acute vesical toxicity caused by high-dose brachytherapy do not affect the survival: a five-year follow-up study. Clin Transl Oncol; 2009 Dec;11(12):828-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vesical instillations of hyaluronic acid to reduce the acute vesical toxicity caused by high-dose brachytherapy do not affect the survival: a five-year follow-up study.
  • METHODS: Single-centre retrospective study of patients diagnosed with cervical and endometrial cancer treated with brachytherapy (BT) with or without intravesical instillation of HA.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Brachytherapy. Genital Neoplasms, Female / drug therapy. Genital Neoplasms, Female / radiotherapy. Hyaluronic Acid / administration & dosage. Radiation Injuries / prevention & control
  • [MeSH-minor] Administration, Intravesical. Aged. Cytoprotection / drug effects. Female. Follow-Up Studies. Humans. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Urinary Bladder / drug effects. Urinary Bladder / radiation effects

  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2005;35(11):940-5 [16249848.001]
  • [Cites] J Urol. 1990 Jan;143(1):139-42 [1688456.001]
  • [Cites] Radiother Oncol. 1997 Feb;42(2):155-61 [9106924.001]
  • [Cites] J Urol. 2006 May;175(5):1624-9 [16600715.001]
  • [Cites] BJU Int. 2004 Jun;93(9):1262-6 [15180619.001]
  • [Cites] BMC Urol. 2005 Mar 23;5:4 [15788101.001]
  • [Cites] World J Urol. 1994;12(1):3-10 [8012413.001]
  • [Cites] Arch Surg. 2002 Mar;137(3):278-82 [11888449.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):935-40 [16376493.001]
  • [Cites] Urology. 1997 May;49(5A Suppl):111-3 [9146012.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Dec;283(6):F1304-12 [12426235.001]
  • [Cites] Cutan Ocul Toxicol. 2006;25(3):165-71 [16980242.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1257-80 [7713787.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2008 May;19(5):717-21 [18097627.001]
  • [Cites] World J Urol. 1994;12(1):11-4 [8012410.001]
  • [Cites] Scand J Urol Nephrol. 2005;39(2):143-7 [16032779.001]
  • (PMID = 20045789.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


45. Komai Y, Kawakita M, Shimada O, Muguruma K, Sakaida N, Matsuda T: Colonic adenocarcinoma and stones in an Indiana pouch. Int J Urol; 2005 Apr;12(4):412-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenocarcinoma and stones in an Indiana pouch.
  • We report on a 63-year-old woman with adenocarcinoma and stones in an Indiana pouch.
  • Adenocarcinoma of an Indiana pouch is extremely rare.
  • To our knowledge, only four cases with adenocarcinoma in an Indiana pouch have been reported.
  • [MeSH-major] Adenocarcinoma / etiology. Colonic Neoplasms / etiology. Colonic Pouches / adverse effects. Urinary Calculi / etiology. Urinary Reservoirs, Continent / adverse effects
  • [MeSH-minor] Anastomosis, Surgical. Biopsy. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Colon / surgery. Colonoscopy. Fatal Outcome. Female. Follow-Up Studies. Humans. Middle Aged. Nephrectomy. Reoperation. Tomography, X-Ray Computed. Ureter / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948733.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


46. Song YS, Cho KH, Kim KW, Yoon JH, Doo SH, Yang WJ, Cho JY, Lee DW: A Case of Bladder Cancer Found during a Workup for Urge Incontinence. Int Neurourol J; 2010 Aug;14(2):130-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Bladder Cancer Found during a Workup for Urge Incontinence.
  • Irritative urinary symptoms may suggest the possibility of bladder cancer.
  • We report a case of metastatic bladder cancer that was discovered during a workup for urge incontinence in a 65-year-old woman with a history of stomach cancer.
  • She had a medical history of gastrectomy due to stomach cancer 4 years previously.
  • Cystoscopy revealed the presence of suspicious bladder mucosal lesions that were biopsied.
  • The pathology was consistent with metastatic signet-ring cell adenocarcinoma.
  • This case suggests that irritative urinary symptoms can be the first clinical manifestation in patients with bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120224.001).
  • [ISSN] 2093-6931
  • [Journal-full-title] International neurourology journal
  • [ISO-abbreviation] Int Neurourol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2989472
  • [Keywords] NOTNLM ; Bladder cancer / Stomach cancer / Urge incontinence
  •  go-up   go-down


47. Jouyaux F, De Crevoisier R, Manens JP, Bellec J, Cazoulat G, Haigron P, Chira C, Le Prisé E, Lafond C: [High dose for prostate irradiation with image guided radiotherapy: contribution of intensity modulation arctherapy]. Cancer Radiother; 2010 Dec;14(8):679-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Haute dose dans la prostate par radiothérapie guidée par l'image: apport de l'arcthérapie avec modulation d'intensité du faisceau.
  • PURPOSE: To compare two Intensity Modulated Radiation Therapy (IMRT) techniques for prostate cancer: the Volumetric Modulated Arc Therapy (VMAT) and the "Step and Shoot" technique (S&S).
  • RESULTS: VMAT, compared to S&S, offered: an increase of the PTV2s (prostate) volume receiving 77 to 80 Gy and a decrease of V(82) and V(83); a decrease of V(4) to V(6), V(16) to V(23), and V(69) to V(73) for the rectal wall; a decrease of V(25) for the bladder wall; a decrease of V(21) to V(43) for the femoral heads; a decrease of V(26) to V(44) and V(72) to V(80) but an increase of V(1) to V(21) and V(49) to V(60) for the healthy tissues.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Organs at Risk / radiation effects. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Femur Head / pathology. Femur Head / radiation effects. Humans. Magnetic Resonance Imaging. Male. Organ Size. Prostate / pathology. Prostate / radiation effects. Radiation Injuries / prevention & control. Radiotherapy Dosage. Rectum / pathology. Rectum / radiation effects. Seminal Vesicles / pathology. Seminal Vesicles / radiation effects. Urinary Bladder / pathology. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • HAL archives ouvertes. Full text from .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20570202.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


48. Puente S, Velasco A, Gallel P, Pallares J, Perez-Ruiz L, Ros S, Maravall J, Matias-Guiu X: Metastatic small cell carcinoma to the thyroid gland: a pathologic and molecular study demonstrating the origin in the urinary bladder. Endocr Pathol; 2008;19(3):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic small cell carcinoma to the thyroid gland: a pathologic and molecular study demonstrating the origin in the urinary bladder.
  • In some cases, demonstration of the primary tumor is not easy.
  • The primary tumor was a small cell carcinoma that occurred as a minor component in a transitional carcinoma of the urinary bladder.
  • The microscopical and immunohistochemical features of both tumors, in the thyroid and the bladder, were identical.
  • Moreover, both tumors exhibited an identical mutation in p53, as well as similar loss of heterozygosity at 10q23 and RASSF1A promoter hypermethylation, clearly indicating that the bladder tumor was the site for the primary tumor of the patient.
  • [MeSH-major] Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / secondary. Thyroid Neoplasms / genetics. Thyroid Neoplasms / secondary. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Base Sequence. Carcinoma, Transitional Cell / pathology. DNA Methylation. DNA Mutational Analysis. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Middle Aged. Neoplasms, Multiple Primary / pathology. Promoter Regions, Genetic / genetics. Prostatic Neoplasms / pathology. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):754-62 [9236831.001]
  • [Cites] Int J Oncol. 1999 Nov;15(5):927-34 [10536175.001]
  • [Cites] J Endocrinol Invest. 2005 Apr;28(4):371-8 [15966513.001]
  • [Cites] Am J Surg Pathol. 1980 Aug;4(4):333-41 [6999920.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(3):267-71 [2166978.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):364-71 [2841895.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):718-23 [16084939.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1172-8 [15700264.001]
  • [Cites] Hum Pathol. 1989 Sep;20(9):896-902 [2550350.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):268-72 [12068173.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2001-4 [16158936.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):957-62 [15329903.001]
  • [Cites] Int J Exp Pathol. 2005 Aug;86(4):213-8 [16045543.001]
  • (PMID = 18446450.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


49. Goulas V, Exarchou V, Troganis AN, Psomiadou E, Fotsis T, Briasoulis E, Gerothanassis IP: Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells. Mol Nutr Food Res; 2009 May;53(5):600-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells.
  • Olive oil compounds is a dynamic research area because Mediterranean diet has been shown to protect against cardiovascular disease and cancer.
  • In this work, we investigated the antioxidant potency and antiproliferative activity against cancer and endothelial cells of water and methanol olive leaves extracts and analyzed their content in phytochemicals using LC-MS and LC-UV-SPE-NMR hyphenated techniques.
  • Olive-leaf crude extracts were found to inhibit cell proliferation of human breast adenocarcinoma (MCF-7), human urinary bladder carcinoma (T-24) and bovine brain capillary endothelial (BBCE).
  • These phytochemicals demonstrated strong antioxidant potency and inhibited cancer and endothelial cell proliferation at low micromolar concentrations, which is significant considering their high abundance in fruits and vegetables.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194970.001).
  • [ISSN] 1613-4133
  • [Journal-full-title] Molecular nutrition & food research
  • [ISO-abbreviation] Mol Nutr Food Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Plant Extracts
  •  go-up   go-down


50. Nimmonrat A, Na-ChiangMai W, Muttarak M: Urachal abnormalities: clinical and imaging features. Singapore Med J; 2008 Nov;49(11):930-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT in all cases showed a mass located extraperitoneally in the midline just beneath the rectus abdominis muscle and extending from the umbilicus to the dome of the urinary bladder.
  • Cystography was performed in one patient and it showed indentation to the dome of the urinary bladder with mucosal irregularity.
  • The other five solid masses were found to be adenocarcinoma in three and chronic non-specific inflammation in two cases.
  • CONCLUSION: Preoperative diagnosis of urachal abnormalities may be suggested by clinical presentation and imaging features.
  • [MeSH-major] Adenocarcinoma / diagnosis. Neoplasms / diagnosis. Urachal Cyst / diagnosis. Urachus / abnormalities
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Urologic Diseases / complications. Urologic Diseases / diagnosis. Urologic Diseases / pathology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037562.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


51. Angeletti C, Harvey NR, Khomitch V, Fischer AH, Levenson RM, Rimm DL: Detection of malignancy in cytology specimens using spectral-spatial analysis. Lab Invest; 2005 Dec;85(12):1555-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite low sensitivity (around 60%), cytomorphologic examination of urine specimens represents the standard procedure in the diagnosis and follow-up of bladder cancer.
  • We believe that, in future, this type of methodology could be used as an ancillary test in cytopathology, in a manner analogous to immunostaining, in those situations when a definitive diagnosis cannot be rendered based solely on the morphology.
  • [MeSH-major] Artificial Intelligence. Cytodiagnosis / methods. Urinary Bladder Neoplasms / diagnosis. Urine / cytology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Humans. Image Processing, Computer-Assisted. Spectrum Analysis. Urinalysis. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200074.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R44 CA88684
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


52. Gilligan T, Dreicer R: The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. Semin Oncol; 2007 Apr;34(2):145-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis.
  • Non-transitional cell neoplasms of the bladder and upper tract transitional cell carcinomas (ureter and renal pelvis) represent only a small fraction of urothelial carcinomas.
  • [MeSH-major] Kidney Neoplasms / therapy. Ureteral Neoplasms / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / therapy. Carcinoma, Small Cell / therapy. Carcinoma, Squamous Cell / therapy. Humans. Kidney Pelvis. Schistosomiasis haematobia / complications. Urachus


53. Subramanya D, Grivas PD, Styler M: Appendiceal carcinoma: a diagnostic and therapeutic challenge. Postgrad Med; 2008 Nov;120(4):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initially, the diagnostic investigation in our patient was focused on urinary tract disorders, but ultimately resulted in finding a mucinous appendiceal carcinoma.
  • The carcinoma had invaded the urinary bladder and was disseminated in the peritoneal cavity.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020371.001).
  • [ISSN] 1941-9260
  • [Journal-full-title] Postgraduate medicine
  • [ISO-abbreviation] Postgrad Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


54. Kojima Y, Yamada Y, Kamisawa H, Sasaki S, Hayashi Y, Kohri K: Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy. Int J Urol; 2006 Aug;13(8):1123-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16903943.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


55. De E, Pisters LL, Pettaway CA, Scott S, Westney OL: Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient reported continence outcomes at 32 months. J Urol; 2007 Jun;177(6):2200-4; discussion 2204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient reported continence outcomes at 32 months.
  • PURPOSE: Salvage prostatectomy after radiation therapy is associated with a high rate of urinary incontinence.
  • To avoid this outcome in candidates with preexisting voiding symptoms, such as frequency, urgency and urge incontinence, we performed concurrent bladder augmentation with bladder neck closure and a catheterizable stoma.
  • Urinary incontinence and patient satisfaction were evaluated.
  • MATERIALS AND METHODS: Between October 2000 and February 2003, 11 patients underwent salvage prostatectomy with bladder neck closure and ileal augmentation using catheterizable appendicovesicostomy or Monti ileovesicostomy.
  • RESULTS: The indication for surgery was recurrent adenocarcinoma of the prostate in 10 patients and invasive squamous cell carcinoma of the urethra in 1.
  • CONCLUSIONS: Continent catheterizable bladder augmentation is a technically feasible option for men requiring salvage prostatectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Cystostomy. Prostatectomy. Prostatic Neoplasms / surgery. Salvage Therapy. Urinary Incontinence / surgery
  • [MeSH-minor] Aged. Feasibility Studies. Follow-Up Studies. Humans. Male. Middle Aged. Patient Satisfaction. Surveys and Questionnaires. Treatment Outcome. Urinary Catheterization

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509319.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Singh I, Hudson JE, Hemal AK: Robot-assisted laparoscopic prostatectomy for a giant prostate with retrieval of vesical stones. Int Urol Nephrol; 2010 Sep;42(3):615-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: An elderly, male with a BMI of 32.49, clinically diagnosed as a case of giant BPH (prior negative prostate biopsy) with vesical stones and severe LUTS, was successfully managed by modified robot assisted laparoscopic technique of prostatectomy with removal of bladder stones.
  • The final histology was predominant BPH with an incidental focal adenocarcinoma within the distal left prostate.
  • Minimally invasive management of massively enlarged prostate with associated bladder stones is a challenging task.
  • The present case of giant prostate enlargement (incidental localized prostate cancer) with vesical stones was successfully managed by a combination of robotic prostatectomy and removal of bladder stones under flexible endoscopic guidance.
  • To the best of our knowledge the present case is the largest (384 g) reported case of cancer prostate (concomitant vesical stone), to be removed by minimally invasive robot assisted laparoscopic technique in the English literature (PubMed™).
  • [MeSH-major] Laparoscopy. Prostatectomy. Prostatic Hyperplasia / surgery. Robotics. Urinary Bladder Calculi / surgery
  • [MeSH-minor] Aged. Cystoscopy. Humans. Incidental Findings. Male. Prostate / pathology. Prostatic Neoplasms / diagnosis


57. Hungerhuber E, Bach E, Hartmann A, Frimberger D, Stief C, Zaak D: Adenocarcinoma of the bladder following nephrogenic adenoma: a case report. J Med Case Rep; 2008;2:164
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the bladder following nephrogenic adenoma: a case report.
  • We report a case of post-traumatic nephrogenic adenoma in a young patient without immunosuppression, which transformed into an adenocarcinoma of the bladder.
  • CASE PRESENTATION: A 25-year-old man had a traumatic bladder perforation caused by a car accident.
  • After physical recovery from the accident, he developed a neurogenic bladder and recurrent urinary tract infections.
  • He presented with nephrogenic adenoma of the bladder 18 months after the accident.
  • The initial pathologic findings were benign, however, the last resection revealed that the former benign adenoma had transformed into a moderately differentiated adenocarcinoma of the bladder (tumor present but no invasion, multifocal, no lymph nodes involved, no metastasis, grade 2).
  • However, patients with nephrogenic adenoma under immunosuppression and patients with neurogenic bladder dysfunction appear to be at a higher risk of developing bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1988 Jan;139(1):130-1 [3121867.001]
  • [Cites] Histopathology. 1990 Jun;16(6):601-4 [2376401.001]
  • [Cites] Urology. 1987 Mar;29(3):237-41 [3548004.001]
  • [Cites] Am J Surg Pathol. 1986 Apr;10(4):268-75 [3706613.001]
  • [Cites] J Urol. 1968 Oct;100(4):466-9 [5677385.001]
  • [Cites] J Urol. 1984 Aug;132(2):263-5 [6737573.001]
  • [Cites] J Urol. 1981 Dec;126(6):824-6 [6798226.001]
  • [Cites] J Urol. 1996 Jul;156(1):41-4 [8648834.001]
  • [Cites] Urology. 1997 Nov;50(5):690-6 [9372876.001]
  • [Cites] Urology. 1999 Feb;53(2):292-7 [9933042.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):117-22 [11954029.001]
  • [Cites] N Engl J Med. 2002 Aug 29;347(9):653-9 [12200552.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2381-2 [14634422.001]
  • [Cites] J Urol. 1950 Nov;64(5):657-70 [14785074.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):117-20 [16360424.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1231-7 [17667548.001]
  • [Cites] Northwest Med. 1949 Mar;48(3):182-5 [18114097.001]
  • [Cites] J Urol. 1988 Jan;139(1):45-7 [3275801.001]
  • (PMID = 18485239.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2396656
  •  go-up   go-down


58. Niu HT, Xu T, Zhang YB, Pang DQ, Zhang ZL, Wu S, Cheng B, Wang Y, Chang JW, Sun G: Outcomes for a large series of radical cystectomies for bladder cancer. Eur J Surg Oncol; 2008 Aug;34(8):911-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes for a large series of radical cystectomies for bladder cancer.
  • AIMS: We present the characteristics and outcomes of a large Chinese series of patients treated with radical cystectomy and pelvic lymphadenectomy for invasive cancer of the bladder.
  • METHODS: The records of 356 patients with invasive bladder cancer, operated at three Chinese medical institutes between 1995 and 2004, were reviewed.
  • Of the 356 patients, 324 (91.0%) were TCC, 24 (6.7%) were adenocarcinoma, eight (2.3%) were squamous carcinoma.
  • CONCLUSIONS: The results of this series show that radical cystectomy and pelvic lymphadenectomy provide durable local control and DFS in patients with invasive bladder cancer.
  • Multivariates affect the prognosis after radical cystectomy for invasive bladder cancer.
  • The treatment of invasive bladder cancer in China is still in need of improvement and normalization.
  • [MeSH-major] Lymph Node Excision. Neoplasm Recurrence, Local. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294806.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Kovylina MV, Pushkar' DIu, Zaĭrat'iants OV, Rasner PI: [Glandular squamous cell carcinoma of the urinary bladder]. Arkh Patol; 2006 Sep-Oct;68(5):35-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glandular squamous cell carcinoma of the urinary bladder].
  • The paper gives a clinical observation of a 52 year-old male with a rare histological urinary bladder tumor primary grandular-squamous-cell carcinoma (pT3N IM0).
  • The tumor is represented by two components large acinic-cell adenocarcinoma and squamous-cell carcinoma with keratinization, which smoothly pass one into another; the tumor has grown through all layers of the urinary bladder wall but it has failed to grow into the peritoneum.
  • Metastases were found in 3 of 8 lymph nodes: one showed high-grade adenocarcinoma and two others displayed average-grade squamous-cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Neoplasms, Glandular and Epithelial / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144529.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


60. Gerst SR, Touijer AK, Guillonneau B, Al-Ahmadie H, Mehdizade A: The importance of MRI evaluation in the preoperative work-up of prostate cancer. Nat Clin Pract Urol; 2005 Nov;2(11):565-71; quiz 572
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of MRI evaluation in the preoperative work-up of prostate cancer.
  • DIAGNOSIS: Poorly differentiated adenocarcinoma of the prostate, with invasion of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Magnetic Resonance Imaging. Prostatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474600.001).
  • [ISSN] 1743-4270
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Taverna G, Corinti M, Colombo P, Grizzi F, Severo M, Piccinelli A, Giusti G, Benetti A, Zucali PA, Graziotti P: Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation. BMC Cancer; 2010;10:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation.
  • BACKGROUND: Appendiceal adenocarcinoma is rare with a frequency of 0.08% of all surgically removed appendices.
  • Few cases of appendiceal carcinoma infiltrating the bladder wall for spatial contiguity have been documented.
  • CASE PRESENTATION: A case is reported of a 45-years old woman with mucinous cystadenocarcinoma of the appendix with bladder metastasis.
  • Although ultrasonography and voided urinary cytology were negative, abdomen computed tomography (CT) scan and cystoscopy and subsequent pathological examination revealed a mass exclusively located in the anterior wall of the bladder.
  • Histopathology of the transurethral bladder resection revealed a bladder adenocarcinoma [6 cm (at the maximum diameter) x 2,5 cm; approximate weight: 10 gr] with focal mucinous aspects penetrating the muscle and perivisceral fat.
  • The subsequent pathological examination revealed a mucinous cystadenocarcinoma of the appendix with metastatic cells colonising the anterior bladder wall and several colic lymph nodes.
  • CONCLUSIONS: The rarity of the appendiceal carcinoma invading the urinary bladder and its usual involvement of nearest organs and the posterior bladder wall, led us to describe this case which demonstrates the ability of the appendiceal cancer to metastasize different regions of urinary bladder.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Cystadenocarcinoma, Mucinous / secondary. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2001 Apr;8(4):196-8 [11260355.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • [Cites] J Urol. 1980 Apr;123(4):590-1 [6245280.001]
  • [Cites] Can J Surg. 1982 Sep;25(5):553-5 [7116255.001]
  • [Cites] J Urol. 1987 Sep;138(3):617-8 [3041057.001]
  • [Cites] J Dig Dis. 2008 Aug;9(3):175-7 [18956597.001]
  • [Cites] Br J Urol. 1996 Aug;78(2):305-6 [8813936.001]
  • [Cites] Urol Int. 1997;58(2):124-7 [9096277.001]
  • [Cites] World J Gastroenterol. 2005 Aug 14;11(30):4761-3 [16094726.001]
  • [Cites] Int Urol Nephrol. 2006;38(3-4):481-2 [17160444.001]
  • [Cites] J Urol. 1995 Apr;153(4):1220-1 [7869505.001]
  • (PMID = 20178637.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2836301
  •  go-up   go-down


62. Rozet F, Lesur G, Cathelineau X, Barret E, Smyth G, Soon S, Vallancien G: Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol; 2008 Jun;179(6):2170-4; discussion 2174-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Prostate sparing cystectomy provides an alternative therapeutic option in highly selected patients with invasive bladder cancer who wish to avoid the significant functional side effects of traditional surgery.
  • Concern exists regarding the oncological safety of this technique especially with regard to the presence of prostatic urothelial cancer and incidental prostate adenocarcinoma.
  • Of 6 patients found to have prostate adenocarcinoma in transurethral prostate resection specimens 1 was treated with high intensity focused ultrasound and 5 were followed with active surveillance, 2 of whom later died of bladder cancer.
  • With appropriate screening the risk of a clinically significant prostate cancer appears to be low.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423740.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Ballardini P, Margutti G, Zangirolami A, Tampieri M, Incasa E, Gamberini S, Manfredini R: Cardiac tamponade as unusual presentation of underlying unrecognized cancer. Am J Emerg Med; 2007 Jul;25(6):737.e5-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade as unusual presentation of underlying unrecognized cancer.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / secondary. Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / secondary. Fatal Outcome. Humans. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Male. Middle Aged. Pericardial Effusion / diagnosis. Pericardial Effusion / etiology. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606115.001).
  • [ISSN] 1532-8171
  • [Journal-full-title] The American journal of emergency medicine
  • [ISO-abbreviation] Am J Emerg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Gatto A, Falvo L, Sebastiani S, Roncolini G, Pinna G: Triple synchronous tumours of the urinary system with different histologies: a case report. Chir Ital; 2009 May-Jun;61(3):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple synchronous tumours of the urinary system with different histologies: a case report.
  • We present the case report of a male patient with a diagnosis of synchronous kidney, bladder and prostate tumours with different histologies: renal oncocytoma, urothelial carcinoma of the bladder, and adenocarcinoma of the prostate.
  • [MeSH-major] Cystectomy. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Nephrectomy. Prostatectomy. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenoma, Oxyphilic / pathology. Aged. Carcinoma / pathology. Humans. Male. Risk Factors. Smoking / adverse effects. Treatment Outcome


65. Bausili M, Cruz C, Alvarez AM, Baxarias P, Hernando D: [Peritoneal absorption of vesical irrigation fluid]. Rev Esp Anestesiol Reanim; 2010 Mar;57(3):190-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Absorción peritoneal de líquido de irrigación vesical.
  • [MeSH-major] Adenocarcinoma / surgery. Intraoperative Complications / chemically induced. Peritoneum / metabolism. Prostatic Neoplasms / surgery. Shock / chemically induced. Solutions / pharmacokinetics. Therapeutic Irrigation. Transurethral Resection of Prostate. Urinary Bladder / injuries

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Shock.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422857.001).
  • [ISSN] 0034-9356
  • [Journal-full-title] Revista española de anestesiología y reanimación
  • [ISO-abbreviation] Rev Esp Anestesiol Reanim
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Electrolytes; 0 / Solutions
  •  go-up   go-down


66. Hamano A, Udagawa K, Nomura S, Ishida T: Inguinal metastasis of a bladder mixed carcinoma with predominant adenocarcinoma component. Scand J Urol Nephrol; 2006;40(1):75-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal metastasis of a bladder mixed carcinoma with predominant adenocarcinoma component.
  • We report a case of urinary bladder mixed carcinoma with inguinal metastasis.
  • Histological examination of the transurethral resection specimens revealed adenocarcinoma with small foci of squamous and transitional cell carcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452061.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


67. Zaghloul MS, Nouh A, Nazmy M, Ramzy S, Zaghloul AS, Sedira MA, Khalil E: Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol; 2006 Jan-Feb;24(1):13-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients.
  • OBJECTIVES: To evaluate the clinical presentation and treatment end results of primary adenocarcinoma of the urinary bladder, and to determine the significant independent prognostic factors that determine this outcome.
  • PATIENTS AND METHODS: Of 3659 patients who underwent cystectomy, 192 had adenocarcinoma of the urinary bladder, with a relative frequency of 5.2%.
  • Mucinous adenocarcinoma was reported in 28 patients (14.6%), papillary in 20 (10.4%), signet ring in 14 (7.3%), while not otherwise specified was reported in 130 (67.7%) in the cystectomy specimens.
  • RESULTS: Mucinous and signet-ring histologic subtypes showed increased frequency of high stages and high grades, and more nodal involvement than the papillary and not otherwise specified.
  • The 5-year disease-free survival rate was 46 +/- 4% for all patients with adenocarcinoma.
  • The disease-free survival independent prognostic variables were tumor stage, postoperative radiotherapy, nodal involvement, and adenocarcinoma subclassification.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Cystectomy. Urinary Bladder Neoplasms / radiotherapy. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16414487.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Torres Gómez FJ, Torres Olivera FJ, Torres Gómez A: [Polypoid cystitis associated with glandular cystic cystitis]. Arch Esp Urol; 2007 Jul-Aug;60(6):692-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Polypoid cystitis and intestinal metaplasia are well-known lesions of the bladder.
  • METHODS: We report the case of one patient with both lesions identified synchronically in the bladder.
  • RESULTS: Although these lesions are not neoplastic, there are evidences supporting a possible degeneration of the metaplastic epithelium to adenocarcinoma.
  • CONCLUSIONS: The diagnosis of both lesions is histological and there are not clinical tests or image studies that could enable identification of the real nature of these lesions.
  • [MeSH-minor] Aged. Cysts / pathology. Humans. Intestines / pathology. Male. Metaplasia / pathology. Polyps / pathology. Urinary Bladder / pathology. Urinary Bladder Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17847746.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


69. Suzuki T, Togo Y, Yasuda K, Yamamoto H, Kokura K, Nagareda T: [Prostatic duct adenocarcinoma with pagetoid spread on the glans penis: a case report]. Hinyokika Kiyo; 2006 Nov;52(11):887-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatic duct adenocarcinoma with pagetoid spread on the glans penis: a case report].
  • The patient underwent total cystoprostatectomy under the diagnosis of urothelial carcinoma of the urinary bladder four years earlier.
  • At the time, the prostatectomy specimen incidentally revealed a prostatic acinar adenocarcinoma at the bilateral peripheral zone.
  • A skin biopsy of the erythema revealed intraepithelial Paget's cells, and the patient underwent total penectomy under the diagnosis of extramammary Paget's disease.
  • Re-examination of the previous prostatectomy specimen revealed prostatic duct adenocarcinoma with prostatic acinar adenocarcinoma.
  • Therefore, the final diagnosis was prostatic duct adenocarcinoma with Pagetoid spread to the glans penis.
  • [MeSH-major] Adenocarcinoma / pathology. Paget Disease, Extramammary / pathology. Penile Neoplasms / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma / pathology. Humans. Male. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17176876.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal cell markers, such as the 34betaE12 antibody and antibodies directed against cytokeratin 5 and 6 or p63, are very useful for demonstration of basal cells as their presence argues against a diagnosis of invasive prostatic carcinoma (PC).
  • However, several benign mimickers of PC, including atrophy, atypical adenomatous hyperplasia (AAH), nephrogenic adenoma, and mesonephric hyperplasia, can stain negatively with these markers, and thus, a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Alpha-methylacyl-coenzyme-A racemase (AMACR) is a sensitive marker of PC (except for a few uncommon variants: atrophic, foamy gland, and pseudohyperplastic variants), and its detection by immunohistochemical staining in atypical prostatic lesions can be very useful in confirming an impression of adenocarcinoma.
  • AMACR expression can also be identified in high grade prostatic intraepithelial neoplasia (PIN), prostatic atrophy, AAH, and benign prostatic glands, and accordingly, a diagnosis of PC should not be based solely on a positive AMACR immunostain, especially when the luminal staining is weak and/or noncircumferential.
  • Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) are both quite sensitive and fairly specific markers of PC (there are a few nonprostatic tumors that can express one or both), and are both very helpful in establishing or confirming the diagnosis of PC when the differential diagnosis includes other tumors that can involve the prostate such as urinary bladder urothelial carcinoma.
  • 34betaE12, p63, thrombomodulin, and uroplakin III are additional urothelial associated markers useful in this differential diagnosis.
  • CDX2 and villin are useful markers to diagnostically separate colonic adenocarcinoma from PC.
  • PSA and PSAP immunohistochemical stains are valuable in confirming metastatic carcinoma as being of prostatic origin and should always be utilized in the diagnostic evaluation of metastatic adenocarcinoma of unknown primary origin in males.
  • [MeSH-major] Carcinoma / diagnosis. Immunohistochemistry. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Neoplasm Metastasis. Sarcoma / diagnosis. Sensitivity and Specificity. Urinary Bladder Neoplasms / diagnosis


71. Thomas AA, Stephenson AJ, Campbell SC, Jones JS, Hansel DE: Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol; 2009 Jan;40(1):108-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder.
  • Signet-ring adenocarcinoma is an aggressive form of primary bladder adenocarcinoma that has been associated with poor outcomes.
  • The utility of immunohistochemical markers in tumors with signet-ring morphology may vary from more typical adenocarcinomas arising at the same location, although this has not been examined in bladder adenocarcinoma.
  • We examined a series of bladder adenocarcinomas to determine the impact of signet-ring cell features on clinical outcomes and immunohistochemical findings.
  • We identified 25 patients with bladder adenocarcinoma, ranging in age from 28 to 78 years (mean, 57 years) and with a male-female ratio of 18:7.
  • Signet-ring cells occurred in 19 of 25 bladder adenocarcinomas (76%) and ranged from 5% to 100% of tumor volume, with most tumors demonstrating more than 60% signet-ring cell differentiation (15/19), when present.
  • A comparison between immunohistochemical markers frequently used to analyze bladder adenocarcinoma demonstrated decreased expression of several markers in signet-ring (n = 9) versus colonic-type (n = 8) morphology, including CDX-2, beta-catenin, and E-cadherin, although these results did not reach statistical significance.
  • In summary, the extent of signet-ring differentiation in bladder adenocarcinoma is associated with worsened survival and higher stage disease; the utility of immunohistochemical analysis in foci consisting of predominant signet-ring cells may be limited, although further studies that address this finding are needed.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Signet Ring Cell / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18789486.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


72. McKenney JK, Amin MB: The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Semin Diagn Pathol; 2005 Feb;22(1):69-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms.
  • The spectrum of neoplasms involving the urinary bladder is diverse, and, at times, different entities with distinct prognostic and managerial implications may have significant morphologic overlap.
  • The presence of a neoplasm with an unusual morphologic appearance, such as an undifferentiated spindled, or plasmacytoid pattern may necessitate immunohistochemistry to establish the diagnosis.
  • In this review, we discuss a series of distinct diagnostic scenarios, including high-grade undifferentiated carcinoma versus prostatic adenocarcinoma, enteric-type adenocarcinoma versus secondary colorectal adenocarcinoma, spindle cell proliferations, neoplasms with plasmacytoid morphology, endophytic tumors with a nested growth pattern, and flat urothelial lesions with atypia.
  • The importance of using a morphologically derived differential diagnosis to guide the selection and interpretation of immunohistochemical studies is emphasized, and the varying utility (specificity) of the individual immunohistochemical markers within each setting is addressed.
  • [MeSH-major] Immunohistochemistry. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Carcinoma / pathology. Child. Diagnosis, Differential. Humans. Male. Neoplasm Metastasis. Neoplasms, Unknown Primary / diagnosis. Precancerous Conditions. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512600.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 62
  •  go-up   go-down


73. Kiuchi H, Ujike T, Miyake O, Namba Y: [A case of further significant anastomotic rupture after gentle traction of urethral catheter for minimal anastomotic leakage after radical retropubic prostatectomy]. Hinyokika Kiyo; 2006 Feb;52(2):151-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 76-year-old man with clinical stage T1c adenocarcinoma of the prostate underwent radical retropubic prostatectomy.
  • However, a cystography on postoperative day 21 showed a displacement of the catheter out of the bladder due to more significant anastomotic rupture.
  • [MeSH-major] Extravasation of Diagnostic and Therapeutic Materials / diagnosis. Prostatectomy / adverse effects. Urethra / surgery. Urinary Bladder / surgery. Urinary Catheterization
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Anastomosis, Surgical / adverse effects. Anastomosis, Surgical / methods. Humans. Magnetic Resonance Imaging. Male. Postoperative Complications. Prostatic Neoplasms / surgery. Rupture. Traction / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541772.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


74. Quek ML, Barry P, Stein JP, Lieskovsky G, Ginsberg DA: Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability. Urology; 2005 May;65(5):964-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability.
  • OBJECTIVES: To determine the outcomes of a select cohort of patients with severe voiding dysfunction, refractory to medical management, and a concomitant diagnosis of prostate cancer, who were treated with radical prostatectomy and augmentation enterocystoplasty.
  • METHODS: Four men with biopsy-proven prostatic adenocarcinoma, as well as a diagnosis of severe overactive bladder, underwent combined radical retropubic prostatectomy and augmentation enterocystoplasty.
  • CONCLUSIONS: The concomitant diagnosis of prostate cancer and severe detrusor instability may be difficult to treat.
  • The results of our study have shown that for those desiring surgical management for their prostate cancer, a combined bladder augmentation and radical prostatectomy may be performed with minimal added morbidity and significantly improved voiding function in the properly selected individual.
  • [MeSH-major] Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / surgery. Urinary Bladder / surgery. Urinary Bladder Diseases / surgery


75. Waalkes MP, Liu J, Ward JM, Diwan BA: Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen. Toxicol Appl Pharmacol; 2006 Sep 15;215(3):295-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen.
  • Arsenic alone also increased lung adenocarcinoma, adrenal cortical adenoma and renal cystic tubular hyperplasia compared to control.
  • The treatments alone did not impact urinary bladder carcinogenesis, but arsenic plus TAM significantly increased formation of urinary bladder transitional cell tumors (papilloma and carcinoma; 13%) compared to control (0%).
  • Urinary bladder proliferative lesions (combined tumors and hyperplasia) were also increased by arsenic plus TAM (40%) or arsenic plus DES (43%) compared to control (0%) or the treatments alone.
  • Urinary bladder proliferative lesions occurred in the absence of any evidence of uroepithelial cytotoxic lesions.
  • Urinary bladder lesions and hepatocellular carcinoma induced by arsenic plus TAM and/or DES overexpressed estrogen receptor-alpha, indicating that aberrant estrogen signaling may have been a factor in the enhanced carcinogenic response.
  • Thus, in male CD1 mice, gestational arsenic exposure alone induced liver adenoma and carcinoma, lung adenocarcinoma, adrenal adenoma and renal cystic hyperplasia.
  • In utero arsenic also initiated urinary bladder tumor formation when followed by postnatal TAM and uroepithelial proliferative lesions when followed by TAM or DES.
  • [MeSH-major] Arsenic / toxicity. Diethylstilbestrol / toxicity. Liver Neoplasms / etiology. Tamoxifen / toxicity. Urinary Bladder Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712894.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens, Non-Steroidal; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic
  •  go-up   go-down


76. Suttmann H, Holl-Ulrich K, Peter M, Kausch I, Doehn C, Jocham D: Mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder. Urology; 2006 Apr;67(4):846.e7-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder.
  • We present a rare case of mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder.
  • For the first time, the unique histopathologic features in this patient provide evidence for the theory that vesical mesonephroid adenocarcinoma might be a highly aggressive metaplastic variant of urothelial carcinoma that should be treated accordingly.
  • [MeSH-major] Adenocarcinoma / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566962.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Mai KT, Ahmed I, Robertson SJ, Belanger EC, Veinot JP, Islam S: Immunocytochemical study of urine cytological preparations from secondary prostatic adenocarcinoma involving the urinary bladder. Diagn Cytopathol; 2008 Oct;36(10):715-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical study of urine cytological preparations from secondary prostatic adenocarcinoma involving the urinary bladder.
  • Involvement of the urinary bladder by prostatic adenocarcinoma (PCA) occasionally occurs.
  • In this study, we analyzed urine cytological findings in patients with secondary involvement of the urinary bladder by PCA with the help of the immunocytochemistry.
  • The diagnosis of PCA was made if the atypical cells were either immunoreactive for PSA or nonreactive for HMWCK.
  • The immunostaining supported the PCA diagnosis in all three cases from the prospective group and two cases in the retrospective group.
  • The positive diagnosis for PCA was based on the PSA immunoreactivity or nonreactivity to HMWCK and the cytological atypia.
  • In conclusions, immunostaining for PSA and HMWCK performed on cytospins of urine specimens from patients with a prior history of high-grade and/or stage of PCA is helpful to make a positive diagnosis of secondary bladder involvement from PCA.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / urine. Prostatic Neoplasms / pathology. Prostatic Neoplasms / urine. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / urine. Urine / cytology


78. Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, el-Baz MA: Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol; 2008 Jul;180(1):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later.
  • PURPOSE: We performed a critical analysis of the results of radical cystectomy for invasive bladder carcinoma treated at 1 center.
  • MATERIALS AND METHODS: Between 1970 and 2000, 2,090 men and 630 women with invasive bladder cancer were treated with 1-stage radical cystectomy and urinary diversion.
  • Squamous tumors accounted for 49.4% of cases, transitional cell carcinoma for 36.4% and adenocarcinoma for 9.6%.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Jul;180(1):12-3 [18485379.001]
  • (PMID = 18485392.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Holten-Andersen MN, Brünner N, Nielsen HJ, Christensen IJ, Sørensen NM, Rasmussen AS, Primdahl H, Orntoft T: Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer. Int J Biol Markers; 2006 Jan-Mar;21(1):6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer.
  • AIM: To assess the potential use of plasma and urine levels of tissue inhibitor of metalloproteinases 1 (TIMP-1) in urothelial cancer.
  • METHODS: TIMP-1 levels were determined in urine and plasma from healthy donors (n=26), patients with bacterial bladder infection (n=24), urothelial bladder adenoma (n=3) or adenocarcinoma (n=7).
  • RESULTS: Free and total TIMP-1 in plasma were weakly but significantly correlated with age; urinary TIMP-1 was not.
  • No significant differences in free or total TIMP-1 in plasma were found between healthy individuals, patients with cystitis or bladder cancer (p=0.4).
  • Urinary TIMP-1 levels were significantly increased in patients with cystitis (p=0.001).
  • No apparent differences in TIMP-1 levels were found in patients with bladder cancer at different stages.
  • Measurement of TIMP-1 in plasma and/or urine is apparently not useful for the identification of bladder cancer.
  • [MeSH-major] Tissue Inhibitor of Metalloproteinase-1 / blood. Tissue Inhibitor of Metalloproteinase-1 / urine. Urinary Bladder Neoplasms / blood. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Aged. Aged, 80 and over. Bacterial Infections / diagnosis. Creatinine / urine. Cystitis / blood. Cystitis / urine. Female. Humans. Male. Middle Aged. Urinary Bladder Diseases / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16711508.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1; AYI8EX34EU / Creatinine
  •  go-up   go-down


80. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S: Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol; 2009 May;33(5):659-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Urachal carcinomas occur mostly in the bladder dome, comprising 22% to 35% of vesical adenocarcinomas, and are generally treated by partial cystectomy with en bloc resection of the median umbilical ligament and umbilicus.
  • RESULT: The mean age at diagnosis was 52 years (range: 26 to 68 y).
  • Thirteen cases were pure adenocarcinoma, not otherwise specified, 9 were enteric type adenocarcinoma, and 2 were adenocarcinoma with focal components of lymphoepithelioma-like carcinoma and urothelial carcinoma with cytoplasmic clearing.
  • In all instances but 1, cystitis cystica/glandularis was focal and predominantly in the bladder overlying the urachal neoplasm.
  • The overlying bladder urothelium was colonized by adenocarcinoma in 3 cases.
  • The mean follow-up period was 40 months (range: 0.3 to 157.6 mo).
  • Surface urothelial involvement by carcinoma and presence of cystitis cystica/glandularis do not necessarily exclude the diagnosis of urachal carcinoma.
  • Immunostains do not unequivocally discriminate a urachal from a colorectal carcinoma, but diffuse positivity for 34BE12 would support, and diffuse nuclear immunoreactivity for beta-catenin would militate against, a diagnosis of urachal carcinoma.
  • Local recurrence may be owing to seeding within the distal urothelial tract, particularly in tumors with a configuration that is polypoid and which open into the bladder cavity.
  • [MeSH-major] Carcinoma / pathology. Urachus / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / pathology. Chemotherapy, Adjuvant. Cystectomy. Cystitis / pathology. Databases as Topic. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome. Umbilicus / surgery. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1380-7 [11684954.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2434-40 [17932892.001]
  • [Cites] J Urol. 2003 Apr;169(4):1295-8 [12629346.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):456-9 [15043458.001]
  • [Cites] J Urol. 1982 Jan;127(1):40-2 [7057501.001]
  • [Cites] Urology. 1983 Apr;21(4):360-6 [6836822.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Urol Res. 1983;11(5):235-8 [6659216.001]
  • [Cites] Urology. 1985 Sep;26(3):218-21 [4035835.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] Hum Pathol. 1996 Mar;27(3):240-7 [8600037.001]
  • [Cites] Cancer. 1955 Jul-Aug;8(4):741-58 [13240656.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):69-87 [16512600.001]
  • [Cites] J Urol. 2006 Jun;175(6):2042-7; discussion 2047 [16697798.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):712-20 [16826585.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):721-8 [16826584.001]
  • [Cites] J Urol. 2007 Jul;178(1):74-8; discussion 78 [17499279.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • (PMID = 19252435.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS627175; NLM/ PMC4225778
  •  go-up   go-down


81. Coote JH, Wylie JP, Cowan RA, Logue JP, Swindell R, Livsey JE: Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Dose escalation for prostate cancer improves biological control but with a significant increase in late toxicity.
  • Recent estimates of low alpha/beta ratio for prostate cancer suggest that hypofractionation may result in biological advantage.
  • METHODS AND MATERIALS: Eligible men had T2-3N0M0 adenocarcinoma prostate, and either Gleason score >or= 7 or prostate-specific antigen 20-50 ng/L.
  • At 2 years, there was 4% Grade 2 bowel and 4.25% Grade 2 bladder toxicity.
  • There was no Grade 3 or 4 bowel toxicity; one patient developed Grade 3 bladder toxicity.
  • UCLA data showed a slight improvement in urinary function at 2 years compared with pretreatment.
  • CONCLUSIONS: These data demonstrate that hypofractionated radiotherapy using IMRT for prostate cancer is well tolerated with minimal late toxicity at 2 years posttreatment.
  • [MeSH-minor] Adenocarcinoma. Aged. Aged, 80 and over. Dose Fractionation. Humans. Intestines / radiation effects. Male. Middle Aged. Prostate-Specific Antigen / blood. Radiation Injuries / complications. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131179.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


82. Nese N, Kesici G, Lekili M, Isisag A: Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report. Anal Quant Cytol Histol; 2010 Jun;32(3):174-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostatic adenocarcinoma (PCa) (Gleason score 6) was diagnosed by needle biopsies.
  • After the diagnosis of high grade, muscle invasive UCa with intact mucosa on frozen examination of the dome of bladder wall during the radical prostatectomy operation (RPO), partial cystectomy was performed.
  • Six months after the diagnosis, an undifferentiated tumor was detected in a bladder transurethral resection specimen; thus, chemotherapy was given.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701072.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Meng Z, Tan J, Dong F, Jia Q, Zhang F: Demonstration of a congenital urine bladder diverticulum by 99mTc-MDP SPET/CT scan in a female with bone metastases. Hell J Nucl Med; 2009 Sep-Dec;12(3):276-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demonstration of a congenital urine bladder diverticulum by 99mTc-MDP SPET/CT scan in a female with bone metastases.
  • Urine bladder diverticula are usually asymptomatic, therefore they are incidentally diagnosed during examinations for other purposes.
  • A Chinese patient, with a history of pulmonary adenocarcinoma first underwent a technetium-99m methylene diphosphonate whole-body bone scan.
  • In addition to multiple skeletal metastases, abnormal shape of the urine bladder was also noted, which overlapped the superior ramus of the right pubic bone.
  • In order to: a) better delineate the shape and structure of the urine bladder;.
  • b) visualize the pubic bone and c) detect the exact location and structural changes of skeletal lesions in the lumbosacral region, single photon emission tomography/computerized tomography (SPET/CT) scan of this region was performed immediately, and demonstrated: a) a big urine bladder diverticulum in the right hemipelvis;.
  • An overview of the etiology, histopathology, complications, management and imaging of urine bladder diverticulum is also presented.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Diverticulum / diagnosis. Lung Neoplasms / diagnosis. Urinary Bladder Diseases / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Incidental Findings. Radiopharmaceuticals. Subtraction Technique. Technetium Tc 99m Medronate. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936344.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


84. Kim TH, Kim DY, Cho KH, Kim YH, Jung KH, Ahn JB, Chang HJ, Kim JY, Choi HS, Lim SB, Sohn DK, Jeong SY: Comparative analysis of the effects of belly board and bladder distension in postoperative radiotherapy of rectal cancer patients. Strahlenther Onkol; 2005 Sep;181(9):601-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of the effects of belly board and bladder distension in postoperative radiotherapy of rectal cancer patients.
  • PURPOSE: To compare the effect of reducing the irradiated small-bowel volume with the use of belly board, bladder distension or both methods combined, in patients with rectal cancer undergoing postoperative pelvic radiotherapy.
  • PATIENTS AND METHODS: This study enrolled 20 consecutive patients with rectal cancer who were scheduled to receive postoperative pelvic radiotherapy.
  • All patients underwent four sets of CT scans under four different methods as follows: group I: empty bladder without the use of a belly board; group II: empty bladder with the use of a belly board; group III: bladder distension without the use of a belly board; group IV: bladder distension with the use of a belly board.
  • CONCLUSION: Bladder distension was a more effective method than the belly board for reducing the irradiated small-bowel volume in postoperative pelvic radiotherapy of rectal cancer patients.
  • The combination of the belly board and bladder distension showed an additive effect and was the most effective method for reducing the irradiated small-bowel volume.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Intestine, Small / radiation effects. Radiotherapy Planning, Computer-Assisted. Rectal Neoplasms / radiotherapy. Urinary Bladder

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170488.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Nakano M, Uno H, Gotoh T, Kubota Y, Ishihara S, Deguchi T, Hayashi S, Matsuo M, Tanaka O, Hoshi H: Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy; 2006 Apr-Jun;5(2):127-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three months after brachytherapy, routine followup kidney-urinary bladder (KUB) radiography showed two seeds that had migrated to the pelvic area and were overlapped by sacral bone.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / adverse effects. Prostatic Neoplasms / radiotherapy. Spine

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644468.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


86. Mazigo HD, Zinga M, Heukelbach J, Rambau P: Case Series of Adenocarcinoma of the Prostate Associated with Schistosoma haematobium Infection in Tanzania. J Glob Infect Dis; 2010 Sep;2(3):307-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case Series of Adenocarcinoma of the Prostate Associated with Schistosoma haematobium Infection in Tanzania.
  • In endemic areas, schistosomiasis has been associated with the pathogenesis of bladder, prostate, colorectal and renal carcinoma.
  • However, the relationship between prostate cancer and schistosomiasis infection remains controversial.
  • Here we present a series of three cases from Tanzania of prostatic adenocarcinoma associated with urinary schistosomiasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20927294.001).
  • [ISSN] 0974-8245
  • [Journal-full-title] Journal of global infectious diseases
  • [ISO-abbreviation] J Glob Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2946689
  • [Keywords] NOTNLM ; Adenocarcinoma / Prostate / Schistosoma haematobium / Schistosomiasis / Tanzania
  •  go-up   go-down


87. Yoshida K, Yamazaki H, Takenaka T, Kotsuma T, Yoshida M, Furuya S, Tanaka E, Uegaki T, Kuriyama K, Matsumoto H, Yamada S, Ban C: A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer. Int J Radiat Oncol Biol Phys; 2010 Jul 1;77(3):765-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer.
  • PURPOSE: To investigate the feasibility of our novel image-based high-dose-rate interstitial brachytherapy (HDR-ISBT) for uterine cervical cancer, we evaluated the dose-volume histogram (DVH) according to the recommendations of the Gynecological GEC-ESTRO Working Group for image-based intracavitary brachytherapy (ICBT).
  • METHODS AND MATERIALS: Between June 2005 and June 2007, 18 previously untreated cervical cancer patients were enrolled.
  • DVHs of the high-risk clinical target volume (HR CTV), intermediate-risk CTV (IR CTV), and the bladder and rectum were calculated.
  • The D(2cc) of the bladder was 62 Gy (range, 51.4-89) and of the rectum was 65.9 Gy (range, 48.9-76).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Ambulatory Care / methods. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Middle Aged. Radiotherapy Dosage. Rectum / radiation effects. Statistics, Nonparametric. Tumor Burden. Urinary Bladder / radiation effects


88. Gobet R, Weber D, Renzulli P, Kellenberger C: Long-term follow up (37-69 years) of patients with bladder exstrophy treated with ureterosigmoidostomy: uro-nephrological outcome. J Pediatr Urol; 2009 Jun;5(3):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow up (37-69 years) of patients with bladder exstrophy treated with ureterosigmoidostomy: uro-nephrological outcome.
  • OBJECTIVE: To describe the urological and nephrological long-term outcome of patients born with classical bladder exstrophy treated with bilateral ureterosigmoidostomies in early childhood.
  • PATIENTS AND METHOD: Out of 42 patients born with bladder exstrophy in Switzerland between 1937 and 1968, 25 participated in this study; seven had died, seven were lost to follow up and three refused consent.
  • All others had different forms of urinary diversions.
  • One patient suffered from adenocarcinoma of the colon, five had benign colonic polyps, one urethral papillary carcinoma and 18 no evidence of tumor.
  • [MeSH-major] Bladder Exstrophy / epidemiology. Bladder Exstrophy / surgery. Postoperative Complications / epidemiology. Ureterostomy. Urinary Diversion
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adolescent. Adult. Aged. Carcinoma, Papillary / epidemiology. Child. Child, Preschool. Colonic Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Urinary Incontinence / epidemiology. Urination. Urolithiasis / epidemiology

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136304.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Reyes Ojeda MD, López Aznar DJ, Abreu Sánchez P, Uruburu Garcia E, Martínez Carsi C, Sopena Monforte R: [Bronchioloalveolar carcinoma as potencial cause of false negative with PET-FDG]. Rev Esp Med Nucl; 2005 Jul-Aug;24(4):254
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinoma bronquioloalveolar como causa potencial de falso negativo con PET-FDG.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radionuclide imaging. Adenocarcinoma, Mucinous / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Neoplasms, Second Primary / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / secondary. Diagnosis, Differential. Humans. Male. Middle Aged. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122411.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Ibele AR, Koplin SA, Slaughenhoupt BL, Kryger JV, Friedl A, Lund DP: Colonic adenocarcinoma in a 13-year-old with cystic fibrosis. J Pediatr Surg; 2007 Oct;42(10):E1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenocarcinoma in a 13-year-old with cystic fibrosis.
  • Here we report a case of colonic adenocarcinoma presenting as pneumaturia in a 13-year-old patient with cystic fibrosis.
  • [MeSH-major] Adenocarcinoma / complications. Cecal Neoplasms / complications. Cystic Fibrosis / complications
  • [MeSH-minor] Adolescent. Air. Anastomosis, Surgical. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Intestinal Fistula / etiology. Intestinal Fistula / surgery. Intestinal Fistula / urine. Leucovorin / administration & dosage. Male. Organoplatinum Compounds / administration & dosage. Urinary Bladder Fistula / etiology. Urinary Bladder Fistula / surgery. Urinary Bladder Fistula / urine. Urine

  • Genetic Alliance. consumer health - BabysFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923181.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


91. Ito H, Hagiwara M, Furuuchi T, Kanai K, Kodaira K, Ninomiya A, Nakamura S: [A case of double cancer involving the urachus and the bladder]. Hinyokika Kiyo; 2010 Jan;56(1):41-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of double cancer involving the urachus and the bladder].
  • We performed cystoscopy, and found a solid tumor at the dome of the bladder.
  • Transurethral resection of bladder tumor was performed.
  • A solid tumor at the dome and two papillary tumors at the right lateral region of the bladder were observed.
  • A pathological examination revealed adenocarcinoma from the solid tumor and urothelial carcinoma from the papillary tumors.
  • Under a diagnosis of double cancer, adenocarcinoma of the urachus and urothelial carcinoma of bladder, we performed a total cystectomy, neobladder and total resection of the urachus.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary / pathology. Urachus. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104009.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. Hirata K, Kanemitsu S, Nakayama Y, Nagata N, Itoh H, Ohnishi H, Ishikawa H, Furukawa Y, HNPCC registry and genetic testing project of the Japanese Society for Cancer of the Colon and Rectum (JSCCR): A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. Am J Gastroenterol; 2006 Jan;101(1):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma.
  • BACKGROUND: One of the clinical features of hereditary nonpolyposis colorectal cancer (HNPCC) is a high incidence of multiple primary neoplasms arising in various organs including the gastrointestinal and genitourinary tracts.
  • METHODS AND RESULTS: A 40-yr-old Japanese patient, who had a past history of adenocarcinoma of the rectum and transitional cell carcinoma of the urinary bladder, developed a liposarcoma in his left thigh.
  • Although his family history did not fulfill the revised Amsterdam criteria, his blood sample was subjected to genetic testing.
  • Direct sequencing of the genomic DNA from the blood identified an AT deletion at codon 677 in exon 13 of hMSH2, a pathogenic mutation that has not been reported before.
  • The expression of MSH2 in the liposarcoma and rectal cancer of the patient was analyzed by immunohistochemistry, which revealed loss of MSH2 expression in the tumors.
  • Since an immunohistochemical analysis showed no nuclear staining for MSH2 protein in the liposarcoma as well as the rectal cancer, the loss of wild-type MSH2 protein was thus considered to possibly play a role in the development of liposarcoma in HNPCC patients.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Liposarcoma / pathology. Muscle Neoplasms / pathology. MutS Homolog 2 Protein / genetics. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Base Pair Mismatch. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Follow-Up Studies. Germ-Line Mutation. Humans. Male. Risk Assessment


93. Gardner JM, Khurana H, Leach FS, Ayala AG, Zhai J, Ro JY: Adenocarcinoma in ectopic prostatic tissue at dome of bladder: a case report of a patient with urothelial carcinoma of the bladder and adenocarcinoma of the prostate. Arch Pathol Lab Med; 2010 Sep;134(9):1271-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in ectopic prostatic tissue at dome of bladder: a case report of a patient with urothelial carcinoma of the bladder and adenocarcinoma of the prostate.
  • We report a case of ectopic prostate tissue with an associated prostatic adenocarcinoma occurring in the dome of the urinary bladder.
  • A 62-year-old man presented with a 4-month history of persistent microscopic hematuria following a urinary tract infection.
  • Cystoscopic examination revealed a sessile lesion of the anterior bladder neck and multiple smaller papillary lesions throughout the bladder.
  • Following a transurethral resection of the bladder tumor with a diagnosis of muscle-invasive transitional cell carcinoma grade 3, a radical cystoprostatectomy was performed.
  • The diagnosis of transitional cell carcinoma was confirmed, but in addition, a different lesion was also incidentally found in the dome of the bladder.
  • This incidental lesion showed a prostatic adenocarcinoma arising from ectopic prostatic tissue within the bladder submucosa.
  • The prostate also showed prostatic adenocarcinoma, but this was minimal, low grade, and confined to the prostate gland, and thus it was felt to be unlikely to have metastasized to the bladder dome.
  • Adenocarcinoma arising in ectopic prostatic tissue is a rare finding and to our knowledge only 1 case has been previously described, occurring in the soft tissue adjacent to the prostate.
  • We report the first case of adenocarcinoma arising in ectopic prostatic tissue within the bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Choristoma / pathology. Neoplasms, Multiple Primary / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20807045.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


94. Orvieto MA, Zorn KC, Gofrit ON, Anderson J, Zagaja GP, Brendler CB: Surgical modifications in bladder neck reconstruction and vesicourethral anastomosis during radical retropubic prostatectomy to reduce bladder neck contractures. Can J Urol; 2006 Dec;13(6):3353-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical modifications in bladder neck reconstruction and vesicourethral anastomosis during radical retropubic prostatectomy to reduce bladder neck contractures.
  • PURPOSE: We describe surgical modifications in radical retropubic prostatectomy (RRP) which have significantly reduced the incidence of bladder neck contractures (BNC).
  • 1) reconstruction of the bladder neck (BN) to a diameter of 28 French;.
  • 2) placement of the posterior (6 o'clock) vesicourethral suture on mild traction before placing this suture into the bladder, allowing inspection and, if necessary, replacement of any of the previously placed sutures;.
  • 3) bladder displacement when tying the vesicourethral sutures which allows the sutures to be tied under direct vision and prevents incorporation of extraneous tissue.
  • Urinary continence (no pads/maximum of one light pad for security in 24 hours) at 12 months in the 32 patients who developed a BNC was worse when compared to patients who did not develop a BNC (58% versus 80%, p = 0.003).
  • The positive margin rate at the BN was not adversely affected by these modifications.
  • [MeSH-major] Contracture / prevention & control. Postoperative Complications / prevention & control. Prostatectomy / methods. Urethra / surgery. Urinary Bladder / surgery. Urinary Bladder Diseases / prevention & control
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Anastomosis, Surgical. Humans. Male. Middle Aged. Prostatic Neoplasms / surgery. Retrospective Studies. Suture Techniques

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187702.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


95. Abol-Enein H, Kava BR, Carmack AJ: Nonurothelial cancer of the bladder. Urology; 2007 Jan;69(1 Suppl):93-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonurothelial cancer of the bladder.
  • In this article, we review available evidence on the treatment of patients with nonurothelial cancer of the bladder.
  • Squamous cell carcinoma and adenocarcinoma are ideally treated with radical cystectomy.
  • Other rarer tumors of the bladder are also discussed.
  • [MeSH-major] Carcinoma, Squamous Cell. Urinary Bladder Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Global Health. Humans. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280911.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  •  go-up   go-down


96. Nag S, Abdou JC, Scruggs G: Use of gold seeds as tumor bed markers. J Surg Oncol; 2005 Nov 1;92(2):147-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Combined Modality Therapy. Humans. Male. Middle Aged. Radiotherapy Dosage. Rectal Neoplasms / pathology. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / radiotherapy. Urinary Bladder Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231371.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 7440-57-5 / Gold
  •  go-up   go-down


97. Jasperson KW, Blazer KR, Lowstuter K, Weitzel JN: Working through a diagnostic challenge: colonic polyposis, Amsterdam criteria, and a mismatch repair mutation. Fam Cancer; 2008;7(4):281-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two most common causes of hereditary colorectal cancer are Lynch syndrome and familial adenomatous polyposis (FAP).
  • The phenotype of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is differentiated in part from FAP by the lack of profuse colonic polyposis.
  • Here we describe a proband who presented with greater than 50 adenomatous colonic polyps prior to developing cancer of the colon and urinary bladder, and a family history that fulfills the Amsterdam criteria.
  • Germline analyses of APC and MYH in the proband did not reveal any mutations.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenomatous Polyposis Coli / complications. Colonic Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. DNA-Binding Proteins
  • [MeSH-minor] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / genetics. Female. Genes, APC. Germ-Line Mutation. Humans. Middle Aged. Neoplasms, Multiple Primary / genetics. Pedigree. Phenotype. Urinary Bladder Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1822-7 [12135043.001]
  • [Cites] Clin Genet. 1998 Oct;54(4):368-70 [9831355.001]
  • [Cites] Gut. 1997 Aug;41(2):235-8 [9301504.001]
  • [Cites] Gene. 2001 Jul 11;272(1-2):301-13 [11470537.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):42-8 [14699485.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Hum Mutat. 2004 Mar;23(3):285 [14974087.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Int J Colorectal Dis. 2006 Jan;21(1):79-83 [16676398.001]
  • [Cites] J Med Genet. 1999 Oct;36(10 ):790-3 [10528862.001]
  • [Cites] Dis Colon Rectum. 1991 May;34(5):424-5 [2022152.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):847-50 [16525781.001]
  • [Cites] J Bacteriol. 1994 Sep;176(17):5393-400 [8071216.001]
  • [Cites] Hum Genet. 2006 Mar;119(1-2):206-11 [16408224.001]
  • [Cites] Gut. 2003 Jun;52(6):898-9 [12740349.001]
  • [Cites] Fam Cancer. 2007;6(1):43-51 [17039270.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10):1022-8 [16234049.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11135-42 [11801590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5908-13 [12732731.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):643-8 [11807791.001]
  • (PMID = 18176851.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043; United States / NCI NIH HHS / CA / R25 CA085771; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCI NIH HHS / CA / R25 CA85771
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein
  •  go-up   go-down


98. Prieto MC, Matousek P, Towrie M, Parker AW, Wright M, Ritchie AW, Stone N: Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue. J Biomed Opt; 2005 Jul-Aug;10(4):44006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue.
  • Prostate samples for this study were obtained by taking a chip at the transurethral resection of the prostate (TURP), and bladder samples from a biopsy taken at transurethral resection of bladder tumor (TURBT) and TURP.
  • Spectra obtained through the bladder and prostate gland tissue, at different time delays after the laser pulse, clearly show change in the spectra as depth profiling occurs, eventually showing signals from the uric acid cell and urea cell, respectively.
  • We show for the first time, using this novel technique, that we are able to obtain spectra from different depths through both the prostate gland and the bladder.
  • This has major implications in the future of Raman spectroscopy as a tool for diagnosis.
  • With the help of Raman spectroscopy and Kerr gating, it may be possible to pick up the spectral differences from a small focus of adenocarcinoma of the prostate gland in an otherwise benign gland, and also stage the bladder cancers by assessing the base of the tumor post resection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / diagnosis. Spectrum Analysis, Raman / methods. Urinary Bladder Neoplasms / chemistry. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Algorithms. Artifacts. Humans. Male. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178640.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Nagai J, Hashimoto T, Togo Y, Fuku K, Yasuda K, Nakao A, Maruyama T, Kondoh N, Nojima M, Takiuchi H, Mori Y, Shima H, Akiyama K: [A case report of bladder hernia associated with prostate cancer]. Hinyokika Kiyo; 2005 Oct;51(10):695-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of bladder hernia associated with prostate cancer].
  • We report a case of bladder hernia.
  • A 68-year-old man was admitted to our hospital for the management of prostate cancer.
  • Magnetic resonance imaging and cystography revealed that the mass was a bladder hernia.
  • During radical prostatectomy, we had to resect the bladder hernia for safe regional lymphadenectomy.
  • The stage of prostate cancer was pT3b N0 M0.
  • This is the third reported case of inguinal bladder hernia associated with prostate cancer in Japan.
  • [MeSH-major] Adenocarcinoma / complications. Hernia, Inguinal / etiology. Prostatic Neoplasms / complications. Urinary Bladder Diseases / etiology


100. Sanli O, Acar O, Celtik M, Oktar T, Kilicaraslan I, Ozcan F, Tunc M, Esen T: Should prostate cancer status be determined in patients undergoing radical cystoprostatectomy? Urol Int; 2006;77(4):307-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should prostate cancer status be determined in patients undergoing radical cystoprostatectomy?
  • INTRODUCTION: We estimate the frequency of prostate cancers detected incidentally in radical cystoprostatectomy specimens and discuss whether the prostate cancer status should be determined in patients undergoing radical cystoprostatectomy.
  • MATERIALS AND METHODS: A total of 97 radical cystoprostatectomies without evidence of prostate cancer on digital rectal examination were performed for transitional cell carcinomas of the bladder between January 2001 and May 2004.
  • RESULTS: The overall incidence of prostate cancer detected in radical cystoprostatectomy specimens was 21.6% (21/97 specimens).
  • CONCLUSIONS: Despite the high prevalence of incidental prostate carcinomas among patients with bladder cancer undergoing cystoprostatectomy, the vast majority of the cancers are organ confined.
  • However, the prostate cancer status should be determined on the basis of digital rectal examination and prostate-specific antigen in patients undergoing radical cystoprostatectomy - especially if prostate-sparing cystectomy is planned.
  • [MeSH-major] Adenocarcinoma / pathology. Cystectomy. Prostatectomy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Diagnosis, Differential. Follow-Up Studies. Humans. Incidence. Intraoperative Period. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17135779.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement